<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Crit Care Med (Targu Mures)</journal-id><journal-id journal-id-type="iso-abbrev">J Crit Care Med (Targu Mures)</journal-id><journal-id journal-id-type="publisher-id">jccm</journal-id><journal-id journal-id-type="doi">jccm</journal-id><journal-title-group><journal-title>The Journal of Critical Care Medicine</journal-title></journal-title-group><issn pub-type="ppub">2393-1809</issn><issn pub-type="epub">2393-1817</issn><publisher><publisher-name>Sciendo</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11864062</article-id><article-id pub-id-type="publisher-id">jccm-2025-0007</article-id><article-id pub-id-type="doi">10.2478/jccm-2025-0007</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Midodrine initiation criteria, dose titration, and adverse effects when administered to treat shock: A systematic review and semi-quantitative analysis</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Puissant</surname><given-names>Madeleine M.</given-names></name><xref rid="j_jccm-2025-0007_aff_001" ref-type="aff"/><email xlink:href="mailto:madeleine.puissant@mainehealth.org">madeleine.puissant@mainehealth.org</email></contrib><contrib contrib-type="author"><name><surname>Armstrong</surname><given-names>Kaitlin J</given-names></name><xref rid="j_jccm-2025-0007_aff_001" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Riker</surname><given-names>Richard R</given-names></name><xref rid="j_jccm-2025-0007_aff_001" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Haydar</surname><given-names>Samir</given-names></name><xref rid="j_jccm-2025-0007_aff_001" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Strout</surname><given-names>Tania D</given-names></name><xref rid="j_jccm-2025-0007_aff_001" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Smith</surname><given-names>Kathryn E</given-names></name><xref rid="j_jccm-2025-0007_aff_001" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Seder</surname><given-names>David B</given-names></name><xref rid="j_jccm-2025-0007_aff_001" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Gagnon</surname><given-names>David J</given-names></name><xref rid="j_jccm-2025-0007_aff_001" ref-type="aff"/></contrib><aff id="j_jccm-2025-0007_aff_001"><institution content-type="dept">Maine Medical Center</institution>,<institution content-type="private"/>
<city>Portland</city>, <country country="US">USA</country></aff></contrib-group><pub-date date-type="pub" publication-format="electronic"><day>31</day><month>1</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><month>1</month><year>2025</year></pub-date><volume>11</volume><issue>1</issue><fpage>5</fpage><lpage>22</lpage><history><date date-type="received"><day>15</day><month>5</month><year>2024</year></date><date date-type="accepted"><day>16</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 Madeleine M. Puissant et al., published by Sciendo</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Madeleine M. Puissant et al., published by Sciendo</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This work is licensed under the Creative Commons Attribution 4.0 International License.</license-p></license></permissions><abstract><title>Abstract</title><sec><title>Objective</title><p>Systematically examine the literature describing midodrine to treat shock and to summarize current administration and dosing strategies.</p></sec><sec><title>Data sources</title><p>Structured literature search conducted in MEDLINE (PubMed) from inception through May 10, 2023.</p></sec><sec><title>Study Selection and Data Extraction</title><p>Abstracts and full texts were assessed for inclusion by two blinded, independent reviewers. English-language publications describing use of midodrine in adult patients with shock were included. Data were extracted by two blinded, independent abstractors using a standardized extraction tool. Quality assessments were completed by paired reviewers using JBI methodology.</p></sec><sec><title>Data Synthesis</title><p>Fifteen of 698 (2%) screened manuscripts were included with 1,714 patients with a variety of shock types. Seven studies (47%) were retrospective, two (13%) prospective observational, and six (40%) randomized controlled studies. Midodrine was initiated to facilitate intravenous vasopressor (IVP) weaning in most (11, 73%) studies; only two (13%) reported IVP weaning protocol use. Starting doses were 10 mg every 8 hours (4, 27%) or three times a day (3, 20%), 20 mg every 8 hours (2, 13%); six studies (40%) did not report initial midodrine dosing. A midodrine titration protocol was reported in 6 (40%) studies. Thirteen (87%) studies evaluated for bradycardia, identified in 6 (46%) studies among 204 patients; only one (0.5%) patient required midodrine discontinuation. Three (20%) studies reported on hypertension with an incidence of 7&#x02013;11%. Four (27%) studies assessed for ischemia; 5/1128 (0.4%) patients experienced mesenteric ischemia requiring midodrine discontinuation.</p></sec><sec><title>Relevance to Patient care and Clinical Practice</title><p>This review explores the pragmatic details involved in initiating, titrating, and weaning midodrine for the bedside clinician and identifies rates of adverse events and complications.</p></sec><sec><title>Conclusions</title><p>Published literature describing midodrine use for shock is heterogeneous and comprised primarily of low or very low quality data. Future controlled trials addressing the shortcomings identified in this systematic review are warranted.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>midodrine</kwd><kwd>shock</kwd><kwd>sepsis</kwd><kwd>critical care</kwd><kwd>systematic review</kwd></kwd-group><counts><page-count count="18"/></counts></article-meta></front><body><sec id="j_jccm-2025-0007_s_001"><title>Introduction</title><p>Midodrine is an oral alpha-1 receptor antagonist that was approved for the treatment of symptomatic ortho-static hypotension by the Food and Drug Administration (FDA) in 1996 [<xref rid="j_jccm-2025-0007_ref_001" ref-type="bibr">1</xref>]. Since then, it has been utilized off-label for blood pressure augmentation in multiple diagnoses, including shock, and its use in the critically ill has increased seven-fold in the past decade [<xref rid="j_jccm-2025-0007_ref_002" ref-type="bibr">2</xref>]. Despite expanding use, important pragmatic issues such as initiation threshold, dose titration parameters, and the clinical relevance of adverse drug effects remain poorly defined.</p><p>Midodrine's prescribing information for orthostatic hypotension recommends a starting dose of 10 mg by mouth three times daily during waking hours to avoid persistent systolic supine hypertension [<xref rid="j_jccm-2025-0007_ref_001" ref-type="bibr">1</xref>]. Single doses of 20 mg and daily doses greater than 30 mg may be tolerated [<xref rid="j_jccm-2025-0007_ref_001" ref-type="bibr">1</xref>]. In the setting of shock, single doses as high as 40 mg, and total daily doses of 120 mg, have been reported in the literature most commonly with every 8 hour dosing intervals [<xref rid="j_jccm-2025-0007_ref_003" ref-type="bibr">3</xref>,<xref rid="j_jccm-2025-0007_ref_004" ref-type="bibr">4</xref>]. Though approved for titration to desired blood pressure with confirmed dose-response effects, many studies have used a fixed-dose regimen which may limit midodrine's effectiveness [<xref rid="j_jccm-2025-0007_ref_001" ref-type="bibr">1</xref>,<xref rid="j_jccm-2025-0007_ref_005" ref-type="bibr">5</xref>,<xref rid="j_jccm-2025-0007_ref_006" ref-type="bibr">6</xref>,<xref rid="j_jccm-2025-0007_ref_007" ref-type="bibr">7</xref>]. The discrepancies between the prescribing information and recent clinical practice warrants further study.</p><p>We are aware of three published meta-analyses that aggregated midodrine effectiveness data from only randomized-controlled trials [<xref rid="j_jccm-2025-0007_ref_008" ref-type="bibr">8</xref>,<xref rid="j_jccm-2025-0007_ref_009" ref-type="bibr">9</xref>,<xref rid="j_jccm-2025-0007_ref_010" ref-type="bibr">10</xref>]. Although randomized-controlled trials (RCTs) are generally considered high quality data, many publications included in prior meta-analyses used fixed-dose approaches without intravenous vasopressor (IVP) weaning protocols and variable outcome criteria. The meta-analyses also focused on clinical outcomes and safety, leaving pragmatic questions unanswered including initiation thresholds, dose titration strategies, and the clinical relevance of adverse drug effects. If these questions can be resolved, the potential for midodrine to decrease ICU length of stay, cost of care, and complications of IVPs may be realized.</p><p>The objective of this systematic review and semi-quantitative analysis was to assess a broader array of published studies to document administration and dosing practices with the goal of improving bedside practice and informing the potential design of future controlled trials.</p></sec><sec id="j_jccm-2025-0007_s_002"><title>Methods</title><sec id="j_jccm-2025-0007_s_002_s_001"><title>Publication Identification</title><p>A structured search of MEDLINE (PubMed) identified all English-language publications with &#x0201c;midodrine&#x0201d; in the title or abstract from inception through May 10, 2023. Publications that met predefined patient, intervention, comparator, and outcome (PICO) criteria were screened for full-text review: <italic toggle="yes">Patients</italic> (adults &#x02265;18 years of age with shock); <italic toggle="yes">Intervention</italic> (midodrine); <italic toggle="yes">Comparator</italic> (not required; studies with and without control groups were included); and <italic toggle="yes">Outcomes</italic> (midodrine dosing and adverse drug effects).</p><p>Two investigators (TDS and DJG) independently screened titles and abstracts for evaluation with a third investigator (RRR) available for disagreements. Publications were excluded if they treated a diagnosis other than shock (e.g., orthostatic hypotension) or were a case report, trial protocol, letter to the editor, conference abstract, systematic review or meta-analysis. Publication references were evaluated during the full-text review.</p></sec><sec id="j_jccm-2025-0007_s_002_s_002"><title>Data Extraction</title><p>Data were extracted by two investigators (MMP and KJA) using a standardized template (<xref rid="j_jccm-2025-0007_fig_001" ref-type="fig">Figure 1</xref>). No protocol was published for this systematic review, but consensus guidance was followed including the Preferred Reporting Items for Systematic review and Meta-Analysis Protocols (PRISMA-P).</p><fig position="float" id="j_jccm-2025-0007_fig_001" fig-type="figure"><label>Fig. 1.</label><caption><p>Preferred reporting items for systematic reviews and meta-analyses (PRISMA) flow diagram</p></caption><graphic xlink:href="j_jccm-2025-0007_fig_001" position="float"/></fig></sec><sec id="j_jccm-2025-0007_s_002_s_003"><title>Patient Characteristics</title><p>Demographic and clinical characteristics included study design, country, patient population including rurality, severity of illness (e.g., APACHE II), shock etiology, renal function at the time of midodrine initiation and during therapy, phase of care (i.e., emergency department or ICU), ICU and hospital length of stay, and mortality.</p></sec><sec id="j_jccm-2025-0007_s_002_s_004"><title>Midodrine Administration</title><p>Midodrine administration data included use of a midodrine dosing protocol, initial and maximum dose and frequency, dosing strategy (titrated or fixed), renal dose adjustments, timing of initiation (before, with, or after IV vasopressors), duration of therapy, route of administration (oral or feeding tube) and continuation at ICU and hospital discharge.</p></sec><sec id="j_jccm-2025-0007_s_002_s_005"><title>Intravenous Vasopressors</title><p>Vasopressor data included dosage and frequency of administration, weaning protocols, number of patients on IVPs at the time of midodrine initiation, central venous catheter duration and complications (e.g., central line-associated bloodstream infections), complications related to IVPs (e.g., extravasation), and time to IVP discontinuation. Vasopressor doses were converted to norepinephrine equivalents as previously described [<xref rid="j_jccm-2025-0007_ref_011" ref-type="bibr">11</xref>].</p></sec><sec id="j_jccm-2025-0007_s_002_s_006"><title>Adverse Drug Effects</title><p>Potential adverse drug effects were determined a priori including bradycardia, bowel or limb ischemia, and stroke. Definitions were according to the study under review and are referred to in this manuscript as present or absent, accordingly.</p></sec><sec id="j_jccm-2025-0007_s_002_s_007"><title>Cost Analyses</title><p>Cost analysis data included direct medical costs per day of patients administered midodrine versus those receiving standard care.</p></sec><sec id="j_jccm-2025-0007_s_002_s_008"><title>Missing Data</title><p>If a data point was not evaluated in a publication, it was classified as &#x0201c;not reported,&#x0201d; and if it was evaluated for but not observed, it was classified as &#x0201c;not observed.&#x0201d; Corresponding authors for publications with missing data were contacted by e-mail, when appropriate.</p></sec><sec id="j_jccm-2025-0007_s_002_s_009"><title>Quality of Evidence Assessment</title><p>Study quality was assessed by two blinded reviewers (MMP and TDS) using the JBI Critical Appraisal Checklists for RCTs, case control studies, case series, and cohort studies [<xref rid="j_jccm-2025-0007_ref_012" ref-type="bibr">12</xref>,<xref rid="j_jccm-2025-0007_ref_013" ref-type="bibr">13</xref>,<xref rid="j_jccm-2025-0007_ref_014" ref-type="bibr">14</xref>]. Studies were evaluated for their methodologic rigor and for potential bias in their design, conduct, and analysis. Initial, pre-discussion interrater agreement on quality appraisal was 0.84, 95% CI: 0.758&#x02013;0.918 using Cohen's kappa statistic. A consensus process was then used to come to a final decision on initial disagreements.</p></sec><sec id="j_jccm-2025-0007_s_002_s_010"><title>Statistical Analysis</title><p>Continuous data are reported as median (interquar-tile range 25<sup>th</sup> &#x02013; 75<sup>th</sup> percentile), and categorical or dichotomous data as number and percentage. This study reports semi-quantitative data; quantitative analyses were not performed given the study objectives and the heterogeneity of aggregated data.</p></sec></sec><sec id="j_jccm-2025-0007_s_003"><title>Results</title><sec id="j_jccm-2025-0007_s_003_s_001"><title>Study Characteristics</title><p>A total of 698 publications were identified and 15 (2%) were included (<xref rid="j_jccm-2025-0007_fig_001" ref-type="fig">Figure 1</xref>) [<xref rid="j_jccm-2025-0007_ref_002" ref-type="bibr">2</xref>,<xref rid="j_jccm-2025-0007_ref_003" ref-type="bibr">3</xref>,<xref rid="j_jccm-2025-0007_ref_004" ref-type="bibr">4</xref>, <xref rid="j_jccm-2025-0007_ref_015" ref-type="bibr">15</xref>,<xref rid="j_jccm-2025-0007_ref_016" ref-type="bibr">16</xref>,<xref rid="j_jccm-2025-0007_ref_017" ref-type="bibr">17</xref>,<xref rid="j_jccm-2025-0007_ref_018" ref-type="bibr">18</xref>,<xref rid="j_jccm-2025-0007_ref_019" ref-type="bibr">19</xref>,<xref rid="j_jccm-2025-0007_ref_020" ref-type="bibr">20</xref>,<xref rid="j_jccm-2025-0007_ref_021" ref-type="bibr">21</xref>,<xref rid="j_jccm-2025-0007_ref_022" ref-type="bibr">22</xref>,<xref rid="j_jccm-2025-0007_ref_023" ref-type="bibr">23</xref>,<xref rid="j_jccm-2025-0007_ref_024" ref-type="bibr">24</xref>,<xref rid="j_jccm-2025-0007_ref_025" ref-type="bibr">25</xref>,<xref rid="j_jccm-2025-0007_ref_026" ref-type="bibr">26</xref>]. Midodrine was administered to 1,714 patients with a median of 31 (20&#x02013;79) patients per study. The first study included patients treated as early as February 2012, with the most recent study including patients treated through April 2021 [<xref rid="j_jccm-2025-0007_ref_015" ref-type="bibr">15</xref>,<xref rid="j_jccm-2025-0007_ref_026" ref-type="bibr">26</xref>]. Seven (47%) studies were retrospective, two (13%) were prospective observational, and six (40%) were RCTs; four of the six (67%) RCTs were open-label. Most studies (12/15; 80%) were single center and conducted in the United States (9/15; 60%) (<xref rid="j_jccm-2025-0007_tab_001" ref-type="table">Table 1</xref>). The primary outcome was time to IVP discontinuation in nine (60%) studies.</p><table-wrap position="float" id="j_jccm-2025-0007_tab_001"><label>Table 1.</label><caption><p>Design of included studies</p></caption><table frame="hsides" rules="rows"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Study</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Design</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Country</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Inclusion Criteria</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Exclusion Criteria</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Primary Outcome</bold>
</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_015" ref-type="bibr">Ahmed Ali 2022</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">RCT; blinding unclear; single center</td><td align="left" valign="top" rowspan="1" colspan="1">Egypt</td><td align="left" valign="top" rowspan="1" colspan="1">Spinal shock in the ICU; age &#x02265;18 years; hemodynamically stable on low-dose NE (&#x0003c;8 mcg/min) monotherapy</td><td align="left" valign="top" rowspan="1" colspan="1">Anuric or oliguric; CKD; allergy</td><td align="left" valign="top" rowspan="1" colspan="1">Total duration of IVP</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_016" ref-type="bibr">Costa-Pinto 2022</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Pilot RCT; open-label; multicenter</td><td align="left" valign="top" rowspan="1" colspan="1">Australia and New Zealand</td><td align="left" valign="top" rowspan="1" colspan="1">Admitted to the ICU; age &#x02265;18 years; clinically stable with hypotension for &#x0003e;24 hours requiring low-dose IVP (&#x02264;10 mcg/min of NE or &#x02264;100 mcg/min of metaraminol) monotherapy</td><td align="left" valign="top" rowspan="1" colspan="1">Lactate &#x0003e;4 mmol/L; renal failure; hemorrhagic, obstructive, or cardiogenic shock; liver failure; severe heart disease; acute brain pathology; pregnancy; thyrotoxicosis; bradycardia (HR &#x0003c;50 bpm), NPO or fed via jejunal tube; allergy</td><td align="left" valign="top" rowspan="1" colspan="1">Time from randomization to discontinuation of IVP</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_019" ref-type="bibr">Davoudi-Monfared 2021</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Pilot RCT; open-label, single-center</td><td align="left" valign="top" rowspan="1" colspan="1">Iran</td><td align="left" valign="top" rowspan="1" colspan="1">Septic shock (MAP &#x0003c;65 mmHg and lactate &#x02265;2 mg/dL despite fluid resuscitation) in the ICU; age &#x02265;18 years; requiring IVP</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02265;24 hours since septic shock onset; CKD (GFR &#x0003c;30 mL/min); neurogenic bladder and urination disorders; PAD; scleroderma, bradycardia (HR &#x0003c;60 bpm); MID PTA</td><td align="left" valign="top" rowspan="1" colspan="1">Lactate clearance at 4, 24 and 48 hours</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_018" ref-type="bibr">Hussein El Adly 2022</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">RCT; open label; single-center</td><td align="left" valign="top" rowspan="1" colspan="1">Egypt</td><td align="left" valign="top" rowspan="1" colspan="1">Septic shock in the ICU; age 18&#x02013;80 years; hypotension (SBP &#x0003c;90 mmHg and MAP &#x0003c;65 mmHg) for &#x0003e;24 hours requiring IVP</td><td align="left" valign="top" rowspan="1" colspan="1">Hypovolemic shock; HF (EF &#x0003c;30%); CKD (SCr &#x0003e;2 mg/dL); thyrotoxicosis; pheochromocytoma; CMO; DDI (MAOIs, alpha-1 blockers, TCAs); orthostatic hypotension; bradycardia (HR &#x0003c;50 bpm); MID PTA; NPO; allergy</td><td align="left" valign="top" rowspan="1" colspan="1">Total duration of IVP; duration of IVP wean; cumulative dose of IVP</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_020" ref-type="bibr">Kim 2021</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Retrospective cohort study; single center</td><td align="left" valign="top" rowspan="1" colspan="1">USA</td><td align="left" valign="top" rowspan="1" colspan="1">Patients admitted to ICU from ED then transferred to floor</td><td align="left" valign="top" rowspan="1" colspan="1">ICU mortality; admitted to ICU due to diabetic ketoacidosis or tissue plasminogen activator administration</td><td align="left" valign="top" rowspan="1" colspan="1">ICU readmission; rapid response team activation; hospital LOS; in-hospital mortality; 30 day hospital readmission</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_021" ref-type="bibr">Lal 2021</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Pilot RCT; double-blinded; multicenter</td><td align="left" valign="top" rowspan="1" colspan="1">USA; United Arab Emirates</td><td align="left" valign="top" rowspan="1" colspan="1">Septic shock (MAP &#x0003c;70 mmHg and SBP &#x0003c;130 mmHg despite antibiotics and fluids 30 mL/kg) in the ICU; age &#x02265;18 years</td><td align="left" valign="top" rowspan="1" colspan="1">ACS or EF &#x0003c;30%; GIB; obstructive or cardiogenic shock; lactate &#x0003e; 4 mmol/L; acute intraabdominal process; transferred from outside facility; cardiac arrest; child-bearing age; thyrotoxicosis; pheochromocytoma; PAD or ischemic bowel; CMO; DDI (MAOIs); bradycardia (HR &#x0003c;40 bpm); MID PTA; NPO; allergy</td><td align="left" valign="top" rowspan="1" colspan="1">Duration of IVP in the first 24 hours</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_026" ref-type="bibr">Levine 2013</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Prospective cohort study; single-center</td><td align="left" valign="top" rowspan="1" colspan="1">USA</td><td align="left" valign="top" rowspan="1" colspan="1">Admitted to the SICU; age &#x02265;18 years; clinically stable (otherwise discharge ready) with hypotension for &#x0003e;24 hours requiring low-dose IVP (phenylephrine &#x0003c;150 mcg/min or NE &#x0003c;8 mcg/min)</td><td align="left" valign="top" rowspan="1" colspan="1">Hypovolemic shock; adrenal insufficiency; &#x0003c;3 doses of MID; orthostatic hypotension; MID PTA</td><td align="left" valign="top" rowspan="1" colspan="1">Time from MID initiation to discontinuation of IVP; Change in IVP rate before/after MID initiation</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_022" ref-type="bibr">Macielak 2021</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Retrospective cohort study; single center</td><td align="left" valign="top" rowspan="1" colspan="1">USA</td><td align="left" valign="top" rowspan="1" colspan="1">Age &#x02265;18 years; receiving MID dosed &#x0201c;four times daily&#x0201d; or &#x0201c;every six hours&#x0201d;</td><td align="left" valign="top" rowspan="1" colspan="1">Incarcerated; pregnancy</td><td align="left" valign="top" rowspan="1" colspan="1">Characterization of patients receiving MID &#x0201c;four times daily&#x0201d; or &#x0201c;every six hours&#x0201d;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_025" ref-type="bibr">Poveromo 2016</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Retrospective cohort study; single-center</td><td align="left" valign="top" rowspan="1" colspan="1">USA</td><td align="left" valign="top" rowspan="1" colspan="1">Admitted to the ICU with diagnosis related to cardiovascular, trauma, or sepsis; age &#x02265;18 years; requiring &#x02265;1 IVP</td><td align="left" valign="top" rowspan="1" colspan="1">ICU mortality within 24 hours; duration of IVP &#x0003c;2 hours; &#x0003c;3 doses of MID; MID for indication other than IVP weaning</td><td align="left" valign="top" rowspan="1" colspan="1">Time from MID initiation to discontinuation of IVP</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_002" ref-type="bibr">Rizvi 2018</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Retrospective case series; single-center</td><td align="left" valign="top" rowspan="1" colspan="1">USA</td><td align="left" valign="top" rowspan="1" colspan="1">Admitted to the ICU; age &#x02265;18 years; initiated on MID</td><td align="left" valign="top" rowspan="1" colspan="1">MID PTA</td><td align="left" valign="top" rowspan="1" colspan="1">Cumulative dose of IVP at MID initiation and 24 hours; MAP at MID initiation and 24 hours</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_003" ref-type="bibr">Rizvi 2019</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Retrospective case series; single-center</td><td align="left" valign="top" rowspan="1" colspan="1">USA</td><td align="left" valign="top" rowspan="1" colspan="1">Admitted to the ICU; age &#x02265;18 years; initiated on MID</td><td align="left" valign="top" rowspan="1" colspan="1">ICU mortality; MID PTA</td><td align="left" valign="top" rowspan="1" colspan="1">Incidence of MID continuation after ICU discharge</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_023" ref-type="bibr">Santer 2020</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">RCT; double-blinded; multicenter</td><td align="left" valign="top" rowspan="1" colspan="1">USA, Australia</td><td align="left" valign="top" rowspan="1" colspan="1">Admitted to the ICU or step-down unit; age &#x02265;18 years; clinically stable with hypotension for &#x0003e;24 hours requiring low-dose (&#x0003c;100 mcg/min phenylephrine, &#x0003c;8 mcg/min of NE, or &#x0003c;60 mcg/min of metaraminol) IVP monotherapy</td><td align="left" valign="top" rowspan="1" colspan="1">Clinical evidence of inadequate tissue oxygenation; adrenal insufficiency; liver failure; CKD (SCr &#x0003e;2 mg/dL); HF (EF &#x0003c;30%); acute urinary retention; pheochromocytoma; thyrotoxicosis; pregnancy; bradycardia (HR &#x0003c;50 bpm); MID PTA; NPO; allergy</td><td align="left" valign="top" rowspan="1" colspan="1">Time from randomization to discontinuation of IVP</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_024" ref-type="bibr">Tremblay 2020</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Retrospective propensity matched cohort study; single center</td><td align="left" valign="top" rowspan="1" colspan="1">Canada</td><td align="left" valign="top" rowspan="1" colspan="1">Admitted to the ICU following cardiac surgery requiring CPB; age &#x02265;18 years; hypotension requiring IVP for &#x0003e;12 hours post-surgery</td><td align="left" valign="top" rowspan="1" colspan="1">MID before surgery; mechanical circulatory support before surgery; emergency surgery; transplantation; cirrhosis</td><td align="left" valign="top" rowspan="1" colspan="1">Number of days alive and free from ICU at 30 days</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_004" ref-type="bibr">Whitson 2016</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Retrospective cohort study; single-center</td><td align="left" valign="top" rowspan="1" colspan="1">USA</td><td align="left" valign="top" rowspan="1" colspan="1">Septic shock in the ICU; clinically stable with hypotension for &#x0003e;24 hours requiring IVP</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">Total duration of IVP; ICU LOS</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Wood 2022</td><td align="left" valign="top" rowspan="1" colspan="1">Retrospective case-control; single center</td><td align="left" valign="top" rowspan="1" colspan="1">Australia</td><td align="left" valign="top" rowspan="1" colspan="1">Admitted to ICU or step-down unit; age &#x02265;18; clinically stable with hypotension for &#x0003e;24 hours requiring low-dose (&#x0003c;8 mcg/min of NE or &#x0003c;60 mcg/min of metaraminol) IVP monotherapy</td><td align="left" valign="top" rowspan="1" colspan="1">Clinical evidence of inadequate tissue oxygenation; adrenal insufficiency; liver failure; CKD (SCr &#x0003e;2 mg/dL); HF (EF &#x0003c;30%); acute urinary retention; pheochromocytoma; thyrotoxicosis; pregnancy; bradycardia (HR &#x0003c;50 bpm); NPO; allergy</td><td align="left" valign="top" rowspan="1" colspan="1">Time from intervention to discontinuation of IVP</td></tr></tbody></table><table-wrap-foot><fn id="j_jccm-2025-0007_tfn_001"><p>Abbreviations: bpm, beats per minute; CPB, cardiopulmonary bypass; CKD, chronic kidney disease; DDI, drug-drug interaction; EF, ejection fraction; GFR, glomerular filtration rate; HR, heart rate; HF, heart failure; ICU, intensive care unit; IVP, intravenous vasopressor; LOS, length of stay; MAOI, monoamine oxidase inhibitors; MAP, mean arterial pressure; mcg, microgram; MICU, medical intensive care unit; MID, midodrine; min, minute; mmol, millimole; NE, norepinephrine; NR, not reported; PAD, peripheral arterial disease; PTA, prior to admission; RCT, randomized-controlled trial; SBP, systolic blood pressure; SICU, surgical intensive care unit; SCr, serum creatinine; TCA, tricyclic antidepressants; TICU, trauma intensive care unit; USA, United States of America.</p></fn></table-wrap-foot></table-wrap></sec><sec id="j_jccm-2025-0007_s_003_s_002"><title>Patient Characteristics</title><p>The most common admitting unit was a medical or mixed ICU (11/15; 73%) followed by a trauma/surgical ICU (7/15; 47%); many included both ICU types (<xref rid="j_jccm-2025-0007_tab_002" ref-type="table">Table 2</xref>). The most common shock type was &#x0201c;mixed&#x0201d; which included cardiogenic, spinal, septic, and postoperative shock/hypotension cases into one category (7/15; 47%) followed by septic only (5/15; 30%). One (7%) study did not report shock type. Severity of illness was defined using APACHE II, III or IV in ten (67%) studies, Euroscore in one (7%), and SOFA score in one (7%); severity of illness was not reported in three (20%) studies. Patients with renal insufficiency, ranging from chronic kidney disease to acute kidney injury, were excluded from seven (47%) studies.</p><table-wrap position="float" id="j_jccm-2025-0007_tab_002"><label>Table 2.</label><caption><p>Patient characteristics and outcomes of included studies</p></caption><table frame="hsides" rules="rows"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Study</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Subjects</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Illness Severity<xref rid="j_jccm-2025-0007_tfn_003" ref-type="table-fn"><sup>*</sup></xref></bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Shock Type</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Renal Function<xref rid="j_jccm-2025-0007_tfn_003" ref-type="table-fn"><sup>*</sup></xref> (SCr in mg/dL)</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Level of Care</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>ICU LOS, d Hospital LOS, d</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1"><bold>ICU Mortality, n (%)</bold><break/>
<bold>Hospital Mortality, n (%)</bold></th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_015" ref-type="bibr">Ahmed Ali 2022</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>TICU</p></list-item><list-item><p>n=30 MID</p></list-item><list-item><p>n=30 Control</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">Spinal</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>MID first day SCr 0.72 &#x000b1; 0.39</p></list-item><list-item><p>Control first day SCr 1.02 &#x000b1; 0.59</p></list-item><list-item><p>p=0.005</p></list-item><list-item><p>MID last day SCr 1.04 &#x000b1; 0.62</p></list-item><list-item><p>Control last day SCr 1.39 &#x000b1; 1.27</p></list-item><list-item><p>p=0.276</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">ICU</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>ICU</p></list-item><list-item><p>MID 5.13 &#x000b1; 1.83</p></list-item><list-item><p>Control 9.03 &#x000b1; 3.74</p></list-item><list-item><p>p&#x0003c;0.001</p></list-item><list-item><p>Hospital&#x02014;NR</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_016" ref-type="bibr">Costa-Pinto 2022</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>MICU</p></list-item><list-item><p>n=32 MID</p></list-item><list-item><p>n=30 Control</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>APACHE III</p></list-item><list-item><p>MID 49.5 (41, 56.25)</p></list-item><list-item><p>Control 48.5 (38.25, 58)</p></list-item><list-item><p>p=0.76</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">Septic; post-op</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>MID SCr 0.82 (0.66, 1.17)</p></list-item><list-item><p>Control SCr 0.83 (0.64, 1.00)</p></list-item><list-item><p>p=0.53</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">ICU</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>ICU</p></list-item><list-item><p>MID 2.08 (1.06, 3.08)</p></list-item><list-item><p>Control 2.46 (1.6, 3.89)</p></list-item><list-item><p>p=0.14</p></list-item><list-item><p>Hospital</p></list-item><list-item><p>MID 9 (5.75, 25.25)</p></list-item><list-item><p>Control 7.5 (6, 14.5)</p></list-item><list-item><p>p=0.92</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>ICU</p></list-item><list-item><p>MID 1 (3.1%)</p></list-item><list-item><p>Control 0 (0%)</p></list-item><list-item><p>p&#x0003e;0.99</p></list-item><list-item><p>Hospital</p></list-item><list-item><p>MID 3 (9.4%)</p></list-item><list-item><p>Control 2 (6.7%)</p></list-item><list-item><p>p&#x0003e;0.99</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_019" ref-type="bibr">Davoudi-Monfared 2021</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>General ICU</p></list-item><list-item><p>n=15 MID</p></list-item><list-item><p>n=13 Control</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>APACHE II</p></list-item><list-item><p>MID 17.06 &#x000b1; 3.15</p></list-item><list-item><p>Control 16.15 &#x000b1; 4.01</p></list-item><list-item><p>p=0.10</p></list-item><list-item><p>SOFA</p></list-item><list-item><p>MID 7.5 &#x000b1; 2.17</p></list-item><list-item><p>Control 8.3 &#x000b1; 2.25</p></list-item><list-item><p>p=0.99</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">Septic</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>MID SCr 1.2 (0.9,1.7)</p></list-item><list-item><p>Control SCr 1.3 (0.85, 1.95)</p></list-item><list-item><p>p=0.95</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">ICU</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>ICU</p></list-item><list-item><p>MID 8 (4, 15)</p></list-item><list-item><p>Control 12 (4.5, 20)</p></list-item><list-item><p>p=0.55</p></list-item><list-item><p>Hospital&#x02014;NR</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>ICU&#x02014;NR</p></list-item><list-item><p>Hospital (28-d)</p></list-item><list-item><p>MID 8 (55.4%)</p></list-item><list-item><p>Control 9 (69.2%)</p></list-item><list-item><p>p=0.32</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_018" ref-type="bibr">Hussein El Adly 2022</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>General ICU</p></list-item><list-item><p>n=30 MID</p></list-item><list-item><p>n=30 Control</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>APACHE II<xref rid="j_jccm-2025-0007_tfn_004" ref-type="table-fn"><sup>**</sup></xref></p></list-item><list-item><p>MID 24 (13&#x02013;39)</p></list-item><list-item><p>Control 21.5 (7&#x02013;39)</p></list-item><list-item><p>SOFA<xref rid="j_jccm-2025-0007_tfn_004" ref-type="table-fn"><sup>**</sup></xref></p></list-item><list-item><p>MID 11.5 (13&#x02013;39)</p></list-item><list-item><p>Control 9 (3&#x02013;20)</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">Septic</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">ICU</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>ICU</p></list-item><list-item><p>Control 11.9 &#x000b1; 7</p></list-item><list-item><p>MID 11.5 &#x000b1; 6.8</p></list-item><list-item><p>p=0.876</p></list-item><list-item><p>Hospital&#x02014;NR</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>ICU</p></list-item><list-item><p>Control 22 (73.3%)</p></list-item><list-item><p>MID 13 (43.4%)</p></list-item><list-item><p>p=0.018</p></list-item><list-item><p>Hospital&#x02014;NR</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_020" ref-type="bibr">Kim 2021</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>ICU to Floor</p></list-item><list-item><p>n=19 MID</p></list-item><list-item><p>n=132 Control</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">Floor (post-ICU)</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>ICU</p></list-item><list-item><p>MID 4.1 &#x000b1; 3.8</p></list-item><list-item><p>Hospital</p></list-item><list-item><p>MID 13.3 &#x000b1; 12.2</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>ICU&#x02014;NR</p></list-item><list-item><p>Hospital</p></list-item><list-item><p>Association between MID and mortality: OR 7.5 (1.3&#x02013;44.5);</p></list-item><list-item><p>p=0.03</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_021" ref-type="bibr">Lal 2021</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>MICU</p></list-item><list-item><p>n=17 MID</p></list-item><list-item><p>n=15 Placebo</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>SOFA</p></list-item><list-item><p>MID 6.8 &#x000b1; 3.3</p></list-item><list-item><p>Placebo 6.3 &#x000b1; 2.6</p></list-item><list-item><p>p=0.64</p></list-item></list></td><td align="left" valign="top" rowspan="1" colspan="1">Septic</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>MID SCr 2.0 &#x000b1; 0.9</p></list-item><list-item><p>Placebo SCr 1.4 &#x000b1; 0.6</p></list-item><list-item><p>p=0.03</p></list-item></list></td><td align="left" valign="top" rowspan="1" colspan="1">ICU</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>ICU</p></list-item><list-item><p>MID 2.29 (1.5, 3.9)</p></list-item><list-item><p>Placebo 2.45 (1.6, 3.2)</p></list-item><list-item><p>p=0.36</p></list-item><list-item><p>Hospital</p></list-item><list-item><p>MID 7 (3.5, 10.5)</p></list-item><list-item><p>Placebo 7 (4, 12)</p></list-item><list-item><p>p=0.41</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_026" ref-type="bibr">Levine 2013</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>SICU</p></list-item><list-item><p>n=20 MID</p></list-item></list></td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>APACHE II</p></list-item><list-item><p>MID 18 &#x000b1; 6</p></list-item></list></td><td align="left" valign="top" rowspan="1" colspan="1">Post-op</td><td align="left" valign="top" rowspan="1" colspan="1">MID SCr 0.74 &#x000b1; 0.28</td><td align="left" valign="top" rowspan="1" colspan="1">ICU</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>ICU time from MID initiation to discharge 4 (3, 6)</p></list-item><list-item><p>Hospital time from MID initiation to discharge 8.5 (5, 16)</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>ICU</p></list-item><list-item><p>1 (5%)</p></list-item><list-item><p>Hospital</p></list-item><list-item><p>1 (5%)</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_022" ref-type="bibr">Macielak 2021</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>General ICU</p></list-item><list-item><p>n=33 MID</p></list-item><list-item><p>Floor</p></list-item><list-item><p>n=11 MID</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">MID SCr 1.56 (0.85, 2.33)</td><td align="left" valign="top" rowspan="1" colspan="1">Any</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>ICU</p></list-item><list-item><p>12 (5, 27)</p></list-item><list-item><p>Hospital&#x02014;NR</p></list-item></list></td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>ICU&#x02014;NR</p></list-item><list-item><p>Hospital</p></list-item><list-item><p>13 (29.5%)</p></list-item></list></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_025" ref-type="bibr">Poveromo 2016</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>MICU, SICU, CVICU, NICU, TICU</p></list-item><list-item><p>n=94 MID</p></list-item><list-item><p>n= 94 Control</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>APACHE IV</p></list-item><list-item><p>MID 59 (44, 83)</p></list-item><list-item><p>Control 82 (66, 93)</p></list-item><list-item><p>p=0.02</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">Cardiogenic; Spinal; Post-op; Septic</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">ICU</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>ICU</p></list-item><list-item><p>MID 5.5 (3, 14.8)</p></list-item><list-item><p>Control 5 (3, 10)</p></list-item><list-item><p>p=0.29</p></list-item><list-item><p>Hospital</p></list-item><list-item><p>MID 12 (8, 21.8)</p></list-item><list-item><p>Control 9.5 (5, 16)</p></list-item><list-item><p>p&#x0003c;0.01</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>ICU&#x02014;NR</p></list-item><list-item><p>Hospital</p></list-item><list-item><p>MID 8 (8.5%)</p></list-item><list-item><p>Control 21 (22.3%)</p></list-item><list-item><p>P=0.01</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_002" ref-type="bibr">Rizvi 2018</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>MICU, SICU, CTICU, TICU, NICU, CICU</p></list-item><list-item><p>n=1119 MID</p></list-item><list-item><p>n=456 no IVP</p></list-item><list-item><p>n=663 yes</p></list-item><list-item><p>IVP</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>APACHE III</p></list-item><list-item><p>MID (no IVP) 76 (62, 93)</p></list-item><list-item><p>MID (yes IVP) 78 (62, 96)</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">Cardiogenic; Spinal; Septic</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>SCr before MID: 1.96</p></list-item><list-item><p>SCr 24 h after MID: 1.94</p></list-item><list-item><p>p=0.3</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">ICU</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>ICU</p></list-item><list-item><p>MID (no IVP) 4 (2, 9)</p></list-item><list-item><p>MID (yes IVP) 6 (3, 14)</p></list-item><list-item><p>Hospital</p></list-item><list-item><p>MID (no IVP) 15 (8, 31)</p></list-item><list-item><p>MID (yes IVP) 18 (8, 37)</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>ICU</p></list-item><list-item><p>MID (no IVP) 35 (8%)</p></list-item><list-item><p>MID (yes IVP) 74 (11%)</p></list-item><list-item><p>Hospital</p></list-item><list-item><p>MID (no IVP) 77 (17%)</p></list-item><list-item><p>MID (yes IVP) 129 (19%)</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_003" ref-type="bibr">Rizvi 2019</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>MICU, SICU, CTICU, TICU, NICU, CICU</p></list-item><list-item><p>n=1010 MID</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>APACHE III</p></list-item><list-item><p>MID 78 &#x000b1; 25.6</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">Cardiogenic; Septic</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">ICU</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>ICU</p></list-item><list-item><p>MID continued at ICU discharge 8.5d &#x000b1; 10.7</p></list-item><list-item><p>MID stopped at ICU discharge 10.6 &#x000b1; 13.4</p></list-item><list-item><p>Hospital&#x02014;NR</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>ICU&#x02014;NR</p></list-item><list-item><p>Hospital</p></list-item><list-item><p>MID continued at ICU discharge</p></list-item><list-item><p>HR 0.45 (0.30&#x02013;0.68), p&#x0003c;0.001</p></list-item><list-item><p>1-year</p></list-item><list-item><p>MID continued at ICU discharge</p></list-item><list-item><p>HR 1.56 (1.23&#x02013;1.99) p&#x0003c;0.001</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_023" ref-type="bibr">Santer 2020</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>SICU, MICU</p></list-item><list-item><p>n=66 MID</p></list-item><list-item><p>n=66 Placebo</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>APACHE II</p></list-item><list-item><p>MID 14.7 &#x000b1; 5.5</p></list-item><list-item><p>Placebo 14.8 &#x000b1; 5.9</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">Septic; Post-op; Other</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>MID SCr 0.8 (0.6, 1.0)</p></list-item><list-item><p>Placebo SCr 0.9 (0.6, 1.3)</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">ICU</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>ICU</p></list-item><list-item><p>MID 6 (5, 8)</p></list-item><list-item><p>Placebo 6 (4, 8)</p></list-item><list-item><p>p=0.46</p></list-item><list-item><p>Hospital</p></list-item><list-item><p>MID 11 (9, 21)</p></list-item><list-item><p>Placebo 14 (9, 22)</p></list-item><list-item><p>p=0.45</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_024" ref-type="bibr">Tremblay 2020</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>CTICU</p></list-item><list-item><p>n=74 MID</p></list-item><list-item><p>n=74 Control</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>Euroscore II</p></list-item><list-item><p>MID 1.94 (1, 2.91)</p></list-item><list-item><p>Control 2.08 (1.31, 4)</p></list-item><list-item><p>p=0.088</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">Vasoplegia after cardiac surgery</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>Acute kidney injury:</p></list-item><list-item><p>MID 11 (14.9%)</p></list-item><list-item><p>Control 10 (13.5%)</p></list-item><list-item><p>p=0.462</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">ICU</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>ICU</p></list-item><list-item><p>MID 4.13 (2.83, 6.08)</p></list-item><list-item><p>Control 2.83 (2, 4.13)</p></list-item><list-item><p>p=0.001</p></list-item><list-item><p>Hospital&#x02014;NR</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>ICU&#x02014;NR</p></list-item><list-item><p>Hospital</p></list-item><list-item><p>MID 10 (13.5%)</p></list-item><list-item><p>Control 1 (1.4%)</p></list-item><list-item><p>p=0.036</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_004" ref-type="bibr">Whitson 2016</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>MICU</p></list-item><list-item><p>n=135 MID</p></list-item><list-item><p>n=140 Control</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>APACHE IV</p></list-item><list-item><p>MID 82.6 &#x000b1; 26.4</p></list-item><list-item><p>Control 84.3 &#x000b1; 26.8</p></list-item><list-item><p>p=0.55</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">Septic</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>Change in SCr:</p></list-item><list-item><p>MID 0.5 &#x000b1; 1.3</p></list-item><list-item><p>Control 0.8 &#x000b1; 1.6</p></list-item><list-item><p>p=0.048</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">ICU</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>ICU</p></list-item><list-item><p>MID 7.5 &#x000b1; 5.9</p></list-item><list-item><p>Control 9.4 &#x000b1; 6.7</p></list-item><list-item><p>p=0.017</p></list-item><list-item><p>Hospital</p></list-item><list-item><p>MID 21.9 &#x000b1; 14.4</p></list-item><list-item><p>Control 24.2 &#x000b1; 14.3</p></list-item><list-item><p>p=0.3</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>ICU</p></list-item><list-item><p>MID 15 (11.1%)</p></list-item><list-item><p>Control 26 (18.6%)</p></list-item><list-item><p>p=0.08</p></list-item><list-item><p>Hospital</p></list-item><list-item><p>MID 31 (23%)</p></list-item><list-item><p>Control 32 (25.7%)</p></list-item><list-item><p>p=0.6</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Wood 2022</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>SICU, MICU</p></list-item><list-item><p>n=19 MID</p></list-item><list-item><p>n=42 Control</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>APACHE II</p></list-item><list-item><p>MID 15 (12, 17)</p></list-item><list-item><p>Control 18.5 (17, 25)</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">Septic, Post-op, Other</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">ICU or step down 
unit</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>ICU</p></list-item><list-item><p>MID 7 (6, 13)</p></list-item><list-item><p>Control 6 (5, 6)</p></list-item><list-item><p>p=0.0058</p></list-item><list-item><p>Hospital</p></list-item><list-item><p>MID 26 (14, 51)</p></list-item><list-item><p>Control 14 (10, 17)</p></list-item><list-item><p>p=0.022</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr></tbody></table><table-wrap-foot><fn id="j_jccm-2025-0007_tfn_002"><p>Medians reported as value (IQR); means reported as value &#x000b1; SD;</p></fn><fn id="j_jccm-2025-0007_tfn_003"><label>*</label><p>baseline values unless otherwise specified;</p></fn><fn id="j_jccm-2025-0007_tfn_004"><label>**</label><p>reported as range instead of IQR.</p></fn><fn id="j_jccm-2025-0007_tfn_005"><p>Abbreviations: APACHE, Acute Physiology and Chronic Health Evaluation; CTICU, cardiothoracic surgery intensive care unit; d, day(s); h, hour(s); ICU, intensive care unit; IVP, intravenous vasopressor; LOS, length of stay; MICU, medical intensive care unit; MID, midodrine; NICU, neurological intensive care unit; NR, not reported; post-op, post-operative; PTA, prior to admission; SCr, serum creatinine; SICU, surgical intensive care unit; SOFA, sequential organ failure assessment; TICU, trauma intensive care unit.</p></fn></table-wrap-foot></table-wrap></sec><sec id="j_jccm-2025-0007_s_003_s_003"><title>Midodrine Administration</title><p>A starting dose of 10 mg every 8 hours (4/15; 27%) or three times daily (3/15; 20%) was most common, with the exception of two (13%) studies that reported a starting dose of 20 mg every 8 hours, and six (40%) that did not report an initial dose (<xref rid="j_jccm-2025-0007_tab_003" ref-type="table">Table 3</xref>). A protocol for midodrine dosing was present in six (40%) studies. Seven (47%) studies used fixed dosing of 10 mg every 8 hours or three times daily and two (13%) used a fixed dose of 20 mg every 8 hours. Doses ranged from 2.5 mg every 12 hours (5 mg total daily dose) to 20 mg every 6 hours to 40 mg every 8 hours (120 mg total daily dose).</p><table-wrap position="float" id="j_jccm-2025-0007_tab_003"><label>Table 3.</label><caption><p>Midodrine Use</p></caption><table frame="hsides" rules="rows"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Study</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Protocol</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Protocol details</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Initial Dose/Frequency</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Max Dose/Frequency</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Titration vs. Fixed Dose</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Start Before, With or After Pressors</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Duration of Midodrine (d)</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Route of Admin</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Continued at ICU Discharge n (%)</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Continued at Hospital Discharge n (%)</bold>
</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_015" ref-type="bibr">Ahmed Ali 2022</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">4 doses of MID, then IVP weaning initiated</td><td align="left" valign="top" rowspan="1" colspan="1">10 mg every 8 h</td><td align="left" valign="top" rowspan="1" colspan="1">10 mg every 8 h</td><td align="left" valign="top" rowspan="1" colspan="1">Fixed</td><td align="left" valign="top" rowspan="1" colspan="1">After</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">PO</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">No</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_016" ref-type="bibr">Costa-Pinto 2022</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>MID administered until off IVP for at least 24 h</p></list-item><list-item><p>Wean: 7.5 mg every 8 h for 24 h, then 5 mg every 8 h for 24 h, then DC</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">10 mg every 8 h</td><td align="left" valign="top" rowspan="1" colspan="1">10 mg every 8 h</td><td align="left" valign="top" rowspan="1" colspan="1">Fixed</td><td align="left" valign="top" rowspan="1" colspan="1">After</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_019" ref-type="bibr">Davoudi-Monfared 2021</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Randomly assigned to adjunctive MID to facilitate IVP wean</td><td align="left" valign="top" rowspan="1" colspan="1">10 mg TID</td><td align="left" valign="top" rowspan="1" colspan="1">10 mg TID</td><td align="left" valign="top" rowspan="1" colspan="1">Fixed</td><td align="left" valign="top" rowspan="1" colspan="1">With</td><td align="left" valign="top" rowspan="1" colspan="1">Up to 5 d</td><td align="left" valign="top" rowspan="1" colspan="1">If conscious, PO; if not, via NGT</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_018" ref-type="bibr">Hussein El Adly 2022</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Randomly assigned to adjunctive midodrine to facilitate IVP wean</td><td align="left" valign="top" rowspan="1" colspan="1">10 mg TID</td><td align="left" valign="top" rowspan="1" colspan="1">10 mg TID</td><td align="left" valign="top" rowspan="1" colspan="1">Fixed</td><td align="left" valign="top" rowspan="1" colspan="1">After</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">PO tablet or crushed (via Ryle)</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_020" ref-type="bibr">Kim 2021</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">No protocol</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">19 (12.6)</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_021" ref-type="bibr">Lal 2021</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">If septic shock without response to antibiotics and fluids, randomized to MID or placebo</td><td align="left" valign="top" rowspan="1" colspan="1">10 mg every 8 h</td><td align="left" valign="top" rowspan="1" colspan="1">10 mg every 8 h</td><td align="left" valign="top" rowspan="1" colspan="1">Fixed</td><td align="left" valign="top" rowspan="1" colspan="1">After or monotherapy</td><td align="left" valign="top" rowspan="1" colspan="1">3 doses</td><td align="left" valign="top" rowspan="1" colspan="1">PO</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">No</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_026" ref-type="bibr">Levine 2013</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">No protocol</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">20 mg TID</td><td align="left" valign="top" rowspan="1" colspan="1">Titration; no details</td><td align="left" valign="top" rowspan="1" colspan="1">After</td><td align="left" valign="top" rowspan="1" colspan="1">4 (3&#x02013;7)</td><td align="left" valign="top" rowspan="1" colspan="1">PO</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_022" ref-type="bibr">Macielak 2021</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">No protocol</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">20 mg every 6 h</td><td align="left" valign="top" rowspan="1" colspan="1">Titration</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>After n=23 (52.3%)</p></list-item><list-item><p>Continued from home n=18 (40.9%)</p></list-item><list-item><p>Monotherapy n=3 (6.8%)</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_025" ref-type="bibr">Poveromo 2016</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">No protocol</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">10 mg every 4 h</td><td align="left" valign="top" rowspan="1" colspan="1">Titration</td><td align="left" valign="top" rowspan="1" colspan="1">After</td><td align="left" valign="top" rowspan="1" colspan="1">4.4 (3.2, 7.8)</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_002" ref-type="bibr">Rizvi 2018</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">No protocol</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">30 mg every 8 h</td><td align="left" valign="top" rowspan="1" colspan="1">Titration</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>After (59%);</p></list-item><list-item><p>Before (41%)</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">PO</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_003" ref-type="bibr">Rizvi 2019</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">No protocol</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">40 mg every 8 h</td><td align="left" valign="top" rowspan="1" colspan="1">Titration</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>After: 58%</p></list-item><list-item><p>Before or monotherapy: 42%</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">11.8 &#x000b1; 20.9</td><td align="left" valign="top" rowspan="1" colspan="1">PO</td><td align="left" valign="top" rowspan="1" colspan="1">672 (67)</td><td align="left" valign="top" rowspan="1" colspan="1">311 (34)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_023" ref-type="bibr">Santer 2020</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Randomized to MID or placebo until ICU discharge. DC&#x02019;ed with stable at goal blood pressure at discretion of clinical team per a standardized weaning protocol (decrease dose every 1&#x02013;2 d from 20 mg to 10 mg every 8 h, then 5 mg every 8 h, then DC)</td><td align="left" valign="top" rowspan="1" colspan="1">20 mg every 8 h</td><td align="left" valign="top" rowspan="1" colspan="1">20 mg every 8 h</td><td align="left" valign="top" rowspan="1" colspan="1">Fixed</td><td align="left" valign="top" rowspan="1" colspan="1">After at least 24 h of IVP</td><td align="left" valign="top" rowspan="1" colspan="1">1.77 (0.98, 2.97)</td><td align="left" valign="top" rowspan="1" colspan="1">PO</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">No</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_024" ref-type="bibr">Tremblay 2020</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">No protocol</td><td align="left" valign="top" rowspan="1" colspan="1">10 mg TID (for n=61, 82.4%)</td><td align="left" valign="top" rowspan="1" colspan="1">Only n=2 with doses 
&#x0003e;10 mg; All TID</td><td align="left" valign="top" rowspan="1" colspan="1">Majority fixed. Progressive 
tapering for n=19 (26%)</td><td align="left" valign="top" rowspan="1" colspan="1">After at least 12 h of IVP</td><td align="left" valign="top" rowspan="1" colspan="1">1.67 (0.96, 3.04)</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">17 (23)</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_004" ref-type="bibr">Whitson 2016</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">No protocol</td><td align="left" valign="top" rowspan="1" colspan="1">10 mg every 8 h</td><td align="left" valign="top" rowspan="1" colspan="1">40 mg every 8 h</td><td align="left" valign="top" rowspan="1" colspan="1">Titration</td><td align="left" valign="top" rowspan="1" colspan="1">After at least 24 h of IVP</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>6.15</p></list-item><list-item><p>For patients who were not discharged on MID (n=117, 86.7%)</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">18 (13.3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Wood 2022</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">Started on MID at discretion of treatment team. If enrolled, MID administered until at least 24 h after DC of IVP</td><td align="left" valign="top" rowspan="1" colspan="1">20 mg every 8 h</td><td align="left" valign="top" rowspan="1" colspan="1">20 mg every 8 h</td><td align="left" valign="top" rowspan="1" colspan="1">Fixed</td><td align="left" valign="top" rowspan="1" colspan="1">After</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">PO</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr></tbody></table><table-wrap-foot><fn id="j_jccm-2025-0007_tfn_006"><p>Medians reported as value (IQR); means reported as value &#x000b1; SD. Abbreviations: d, day(s); DC, discontinued or discontinuation; h, hour(s); ICU, intensive care unit; IVP, intravenous vasopressors; MID, midodrine; mg, milligrams; NGT, nasogastric tube; NR, not reported; PO, by mouth; TID, three times daily</p></fn></table-wrap-foot></table-wrap><p>No study adjusted the midodrine dose for renal function though one did recommend a lower starting dose for patients with kidney dysfunction [<xref rid="j_jccm-2025-0007_ref_027" ref-type="bibr">27</xref>]. Most studies reported administering midodrine orally (7/15; 47%), but many did not specify if this was given by mouth or through a feeding tube, and only two explicitly stated they crushed or administered it via gastrostomy tube [<xref rid="j_jccm-2025-0007_ref_018" ref-type="bibr">18</xref>,<xref rid="j_jccm-2025-0007_ref_019" ref-type="bibr">19</xref>]. Midodrine was initiated in the ICU in a majority of publications (14/15; 93%). No studies included patients in the emergency department.</p><p>Two (13%) studies specified weaning protocols for midodrine including decreasing the dose from 10 mg to 7.5 mg every 8 hours for 24 hours, then 5 mg every 8 hours for 24 hours, then discontinuation or decreasing the dose every 1&#x02013;2 days from 20 mg to 10 mg every 8 hours, then 5 mg every 8 hours, then discontinuation [<xref rid="j_jccm-2025-0007_ref_016" ref-type="bibr">16</xref>,<xref rid="j_jccm-2025-0007_ref_023" ref-type="bibr">23</xref>]. Six studies (40%) reported midodrine continuation past ICU discharge (range: 13&#x02013;67% of patients) and three (20%) studies reported it was continued at hospital discharge (range: 13&#x02013;52% of patients).</p></sec><sec id="j_jccm-2025-0007_s_003_s_004"><title>Intravenous Vasopressors</title><p>Midodrine was initiated to wean off IVPs during shock resolution in most studies (11/15; 73%) with a minority describing its use before or with IVPs during the early phase of shock (5/15; 30%). Nine (60%) studies reported that all patients were on IVPs when midodrine was initiated, and in the other six studies, 48% to 59% of patients were being treated with IVPs (<xref rid="j_jccm-2025-0007_tab_004" ref-type="table">Table 4</xref>). The number of IVPs administered at midodrine initiation was reported in ten (67%) studies and most (8/10; 80%) reported only one IVP (norepinephrine, phenylephrine, or metaraminol). The median dose of IVPs, expressed as norepinephrine equivalents, was 0.08 (0.05&#x02013;0.14) mcg/kg/min. No study exclusively looked at patients not on IVPs and only two (13%) specified a weaning procedure for IVPs [<xref rid="j_jccm-2025-0007_ref_015" ref-type="bibr">15</xref>,<xref rid="j_jccm-2025-0007_ref_018" ref-type="bibr">18</xref>].</p><table-wrap position="float" id="j_jccm-2025-0007_tab_004"><label>Table 4.</label><caption><p>Intravenous Vasopressor Use</p></caption><table frame="hsides" rules="rows"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Study</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Percent of patients on IVP at MID initiation, n (%)</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Number of IVP at MID initiation</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>NEE at MID initiation</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Time to IVP discontinuation (h)</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Need to restart IVP, n (%)</bold>
</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_015" ref-type="bibr">Ahmed Ali 2022</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>MID 30 (100)</p></list-item><list-item><p>Control 30 (100)</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">1 (NE only)</td><td align="left" valign="top" rowspan="1" colspan="1">NR; inclusion criteria &#x0003c;8 mcg/min NE</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>MID 79.2 &#x000b1; 31.7</p></list-item><list-item><p>Control 166.3 &#x000b1; 55.7</p></list-item><list-item><p>p&#x0003c;0.001</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_016" ref-type="bibr">Costa-Pinto 2022</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>MID 32 (100)</p></list-item><list-item><p>Control 30 (100)</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">1 (NE or metaraminol)</td><td align="left" valign="top" rowspan="1" colspan="1">NR; inclusion criteria &#x0003c;10 mcg/min NE or &#x0003c;100 mcg/min metaraminol</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>MID 16.5 (7.2, 27.5)</p></list-item><list-item><p>Control 19 (12.2, 38.5)</p></list-item><list-item><p>p=0.32</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>MID 6 (18.8)</p></list-item><list-item><p>Control 4 (13.3)</p></list-item><list-item><p>p=0.73</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_019" ref-type="bibr">Davoudi-Monfared 2021</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>MID 15 (100)</p></list-item><list-item><p>Control 13 (100)</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">1 (NE only)</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>Midodrine median NEE 0.14 mcg/kg/min</p></list-item><list-item><p>Control median NEE 0.13 mcg/kg/min</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>MID 96 (48, 192)</p></list-item><list-item><p>Control 120 (72, 264)</p></list-item><list-item><p>p=0.36</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>MID 4 (26.7)</p></list-item><list-item><p>Control 5 (38.5)</p></list-item><list-item><p>p=0.39</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_018" ref-type="bibr">Hussein El Adly 2022</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>MID 30 (100)</p></list-item><list-item><p>Control 30 (100)</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">1 (NE only)</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>Midodrine median NEE 0.08, range 0.04&#x02013;0.21 mcg/kg/min</p></list-item><list-item><p>Control median NEE 0.11, range 0.02&#x02013;0.35 mcg/kg/min</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>MID 26 (14, 106)</p></list-item><list-item><p>Control 78.5 (32, 280)</p></list-item><list-item><p>p&#x0003c;0.001</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>MID 3 (10%)</p></list-item><list-item><p>Control 3 (10%)</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_020" ref-type="bibr">Kim 2021</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">All 73 (48.3)</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_021" ref-type="bibr">Lal 2021</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>MID 11 (52.4)</p></list-item><list-item><p>Placebo 10 (47.6)</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>Requiring IVP at 12 h:</p></list-item><list-item><p>MID 41.2% vs Control 60%</p></list-item><list-item><p>p=0.29</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_026" ref-type="bibr">Levine 2013</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">MID 20 (100)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (NE or PE)</td><td align="left" valign="top" rowspan="1" colspan="1">Midodrine mean NEE 4.1 mcg/min</td><td align="left" valign="top" rowspan="1" colspan="1">MID 17 (7, 38.4)</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_022" ref-type="bibr">Macielak 2021</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">MID 23 (52.3)</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">Midodrine mean NEE 0.1 mcg/kg/min</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_025" ref-type="bibr">Poveromo 2016</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>MID 94 (100)</p></list-item><list-item><p>Control 94 (100)</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>MID: 1 (40.4%), 2 (41.5%), 3+ (18.1%)</p></list-item><list-item><p>Control: 1 (62.8%), 2 (24.4%), 3+ (12.8%)</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>Midodrine median NEE 0.05 (0.03, 0.08) mcg/kg/min</p></list-item><list-item><p>Control median NEE 0.05 (0.03, 0.08) mcg/kg/min</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>MID 28.8 (12, 67.2)</p></list-item><list-item><p>Control: NR</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>MID 42 (44.7)</p></list-item><list-item><p>Control: NR</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_002" ref-type="bibr">Rizvi 2018</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">MID 663 (59.0)</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">Midodrine median NEE 0.24 mcg/kg/min</td><td align="left" valign="top" rowspan="1" colspan="1">Requiring IVP at 24 h: 48%</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_003" ref-type="bibr">Rizvi 2019</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">MID 587 (58.1)</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">Midodrine median NEE 0.19 mcg/kg/min</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_023" ref-type="bibr">Santer 2020</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>MID 66 (100)</p></list-item><list-item><p>Placebo 66 (100)</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">1 (NE, PE, or metaraminol)</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>Midodrine median NEE 0.03 (0.02, 0.06) mcg/kg/min</p></list-item><list-item><p>Control median NEE 0.03 (0.02, 0.06) mcg/kg/min</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>MID 23.5 (10.4, 44)</p></list-item><list-item><p>Control 22.5 (10.4, 40)</p></list-item><list-item><p>p=0.62</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_024" ref-type="bibr">Tremblay 2020</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>MID 74 (100)</p></list-item><list-item><p>Control 74 (100)</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>MID: 1 (85.1%), 2 (13.5%), 3 (1.4%)</p></list-item><list-item><p>Control: NR</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">All patients median NEE 0.05 (0.03, 0.09) mcg/kg/min</td><td align="left" valign="top" rowspan="1" colspan="1">MID 19 (4, 44)</td><td align="left" valign="top" rowspan="1" colspan="1">MID 16 (21.6)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_004" ref-type="bibr">Whitson 2016</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>MID 135 (100)</p></list-item><list-item><p>Control 140 (100)</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">1 (NE or PE)</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>Midodrine mean NEE 0.09 mcg/kg/min</p></list-item><list-item><p>Control mean NEE NR</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>MID 69.6 &#x000b1; NR</p></list-item><list-item><p>Control 91.2 &#x000b1; NR</p></list-item><list-item><p>p&#x0003c;0.001</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>MID 7 (5.2)</p></list-item><list-item><p>Control 21 (15)</p></list-item><list-item><p>p=0.007</p></list-item></list>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Wood 2022</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>MID 19 (100)</p></list-item><list-item><p>Control 42 (100)</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">1 (NE or metaraminol)</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>Midodrine median NEE 0.05 mcg/kg/min</p></list-item><list-item><p>Control median NEE 0.08 mcg/kg/min</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>MID 26 (22, 36)</p></list-item><list-item><p>Control 24 (17, 93)</p></list-item><list-item><p>p=0.511</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr></tbody></table><table-wrap-foot><fn id="j_jccm-2025-0007_tfn_007"><p>Medians reported as value (IQR); means reported as value &#x000b1; SD. Abbreviations: IVP, intravenous vasopressors; kg, kilogram; mcg, microgram; MID, midodrine; min, minute; NE, norepinephrine; NEE, norepinephrine equivalents; NR, not reported; PE, phenylephrine.</p></fn></table-wrap-foot></table-wrap><p>There were no reports of IVP-related or central venous catheter-related complications. Only one (6%) study reported that the midodrine group required a shorter duration of central venous catheterization, but the finding was not statistically significant [<xref rid="j_jccm-2025-0007_ref_021" ref-type="bibr">21</xref>]. The time to IVP discontinuation, the most common primary outcome studied, was 26 (20.1&#x02013;59.4) hours for the midodrine patients and 78.5 (23.3&#x02013;105.6) for controls.</p></sec><sec id="j_jccm-2025-0007_s_003_s_005"><title>Adverse Drug Effects</title><p>Thirteen (87%) studies reported the incidence of bradycardia with six (46%) reporting it was present (<xref rid="j_jccm-2025-0007_tab_005" ref-type="table">Table 5</xref>). The definition for bradycardia varied and was generally defined as a heart rate &#x0003c;40&#x02013;60 beats per minute. Of the 204 individual patients with bradycardia, only one (0.5%) required midodrine discontinuation and none required a medical intervention (e.g., atropine) [<xref rid="j_jccm-2025-0007_ref_004" ref-type="bibr">4</xref>].</p><table-wrap position="float" id="j_jccm-2025-0007_tab_005"><label>Table 5.</label><caption><p>Reported Side Effects</p></caption><table frame="hsides" rules="rows"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Study</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Bradycardia Definition</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Bradycardia Incidence, n (%)</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Heart Rate Change (bpm)</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Bradycardia Interventions</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Bowel Ischemia n (%)</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Peripheral Ischemia n (%)</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Cerebral Ischemia n (%)</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Allergy n (%)</bold>
</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_015" ref-type="bibr">Ahmed Ali 2022</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">No definition</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>MID Day 1: 117 &#x000b1; 14.2,</p></list-item><list-item><p>MID Mid-study: 103.77 &#x000b1; 16.65,</p></list-item><list-item><p>MID Last Day: 79 &#x000b1; 16.9</p></list-item><list-item><p>Control Day 1: 120.43 &#x000b1; 14.64</p></list-item><list-item><p>Control Mid-study: 97.1 &#x000b1; 16.65</p></list-item><list-item><p>Control Last Day: 96.73 &#x000b1; 18.75</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_016" ref-type="bibr">Costa-Pinto 2022</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Bradycardia: &#x02264;50 bpm; Severe bradycardia: &#x0003c;40 bpm</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>Bradycardia within 24 h:</p></list-item><list-item><p>MID 10 (31.2)</p></list-item><list-item><p>Control 2 (6.7)</p></list-item><list-item><p>p=0.02</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>Baseline MID HR: 76 (70, 85)</p></list-item><list-item><p>Baseline Control HR: 77.5 (65.5, 85)</p></list-item><list-item><p>p=0.61</p></list-item><list-item><p>MID HR over 24 h: 69 (62, 82)</p></list-item><list-item><p>Control HR over 24 h: 74 (67, 83)</p></list-item><list-item><p>p=0.21</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">None; episodes of bradycardia, except one, were transient and deemed clinically insignificant</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NO</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_019" ref-type="bibr">Davoudi-Monfared 2021</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;60 bpm</td><td align="left" valign="top" rowspan="1" colspan="1">NO</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_018" ref-type="bibr">Hussein El Adly 2022</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;50 bpm</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_020" ref-type="bibr">Kim 2021</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_021" ref-type="bibr">Lal 2021</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;40 bpm and symptomatic</td><td align="left" valign="top" rowspan="1" colspan="1">NO</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">NO</td><td align="left" valign="top" rowspan="1" colspan="1">NO</td><td align="left" valign="top" rowspan="1" colspan="1">NO</td><td align="left" valign="top" rowspan="1" colspan="1">NO</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_026" ref-type="bibr">Levine 2013</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">No definition</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>Before MID HR 82 &#x000b1; 13</p></list-item><list-item><p>After MID HR 81 &#x000b1; 15</p></list-item><list-item><p>p=0.66</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_022" ref-type="bibr">Macielak 2021</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;50 bpm</td><td align="left" valign="top" rowspan="1" colspan="1">NO</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">1 (2.3)</td><td align="left" valign="top" rowspan="1" colspan="1">NO</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_025" ref-type="bibr">Poveromo 2016</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;60 bpm for two consecutive readings</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>MID: 12 (12.8)</p></list-item><list-item><p>Control: NR</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_002" ref-type="bibr">Rizvi 2018</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02264;50 bpm; &#x02264;40 bpm</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#x02264;50 bpm: 172 (15.4)</p></list-item><list-item><p>&#x02264;40 bpm: 100 (9)</p></list-item><list-item><p>Lowest HR: 39 (33, 44)</p></list-item><list-item><p>bpm</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">None</td><td align="left" valign="top" rowspan="1" colspan="1">2 (0.18)</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NO</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_003" ref-type="bibr">Rizvi 2019</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_023" ref-type="bibr">Santer 2020</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;40 bpm or &#x02265;20% decrease from a pre-specified goal</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>MID: 5 (7.6)</p></list-item><list-item><p>Control: 0 (0)</p></list-item><list-item><p>p=0.02</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_024" ref-type="bibr">Tremblay 2020</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">No definition</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">2 (2.7)</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_004" ref-type="bibr">Whitson 2016</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">No definition</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>MID: 1 (0.7)</p></list-item><list-item><p>Control: NO</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">MID discontinued and bradycardia resolved.</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Wood 2022</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;40 bpm or &#x02265;20% decrease from a pre-specified goal</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>MID: 4 (22)</p></list-item><list-item><p>Control: 1 (2.4)</p></list-item><list-item><p>p=0.025</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">No significant change</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr></tbody></table><table-wrap-foot><fn id="j_jccm-2025-0007_tfn_008"><p>Medians reported as value (IQR); means reported as value &#x000b1; SD; Abbreviations: bpm, beats per minute; MID, midodrine; HR, heart rate; NR, not reported; NA, not applicable; NO, not observed; SCr, serum creatinine.</p></fn></table-wrap-foot></table-wrap><p>Three (20%) studies reported the incidence of hypertension using various definitions, most commonly a systolic blood pressure &#x0003e;160 mmHg. The incidence of hypertension ranged from 5.6%&#x02013;10.6% in the studies that reported it. None of the studies reported hypertension as a reason for midodrine discontinuation.</p><p>Four (27%) studies assessed for ischemia, either mesenteric or peripheral, with limited description on how it was assessed. Five (5/1128; 0.4%) patients in the four studies developed mesenteric ischemic requiring midodrine discontinuation. Three of the five had alternative explanations (e.g., multiple high-dose IVPs) but two did not. No peripheral (e.g., digits and limb) ischemia was observed.</p></sec><sec id="j_jccm-2025-0007_s_003_s_006"><title>Cost Analyses</title><p>One study conducted a cost analysis and reported direct medical cost per day in midodrine patients was $2,776.50 compared to $2,454.00 in control patients. Indirect medical costs were not considered.<sup>18</sup></p></sec><sec id="j_jccm-2025-0007_s_003_s_007"><title>Quality of Evidence Assessment</title><p>Evaluation using the JBI Critical Appraisal Checklist criteria for randomized controlled trials, case control studies, case series, and cohort studies, revealed varied adherence to bias-reducing strategies within individual study designs (<xref rid="j_jccm-2025-0007_tab_006" ref-type="table">Table 6</xref>). Few studies (5/15, 33.3%) met all bias-reduction criteria for their study type, with the majority of studies (10/15, 66.7%) being at risk for the introduction of bias in at least one facet of the study [<xref rid="j_jccm-2025-0007_ref_002" ref-type="bibr">2</xref>,<xref rid="j_jccm-2025-0007_ref_022" ref-type="bibr">22</xref>,<xref rid="j_jccm-2025-0007_ref_023" ref-type="bibr">23</xref>,<xref rid="j_jccm-2025-0007_ref_024" ref-type="bibr">24</xref>,<xref rid="j_jccm-2025-0007_ref_026" ref-type="bibr">26</xref>]. Importantly, five of six randomized controlled studies were at significant risk of bias with only one study employing all assessed methods of bias reduction [<xref rid="j_jccm-2025-0007_ref_015" ref-type="bibr">15</xref>,<xref rid="j_jccm-2025-0007_ref_016" ref-type="bibr">16</xref>,<xref rid="j_jccm-2025-0007_ref_018" ref-type="bibr">18</xref>,<xref rid="j_jccm-2025-0007_ref_019" ref-type="bibr">19</xref>,<xref rid="j_jccm-2025-0007_ref_021" ref-type="bibr">21</xref>,<xref rid="j_jccm-2025-0007_ref_023" ref-type="bibr">23</xref>].Full details of quality assessments are provided in <xref rid="j_jccm-2025-0007_tab_006" ref-type="table">Table 6</xref>.</p><table-wrap position="float" id="j_jccm-2025-0007_tab_006"><label>Table 6.</label><caption><p>Quality appraisal for included studies by study design</p></caption><table frame="hsides" rules="rows"><thead><tr><th colspan="13" align="left" valign="middle" rowspan="1">
<bold>Randomized controlled trials</bold>
</th></tr><tr><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Study</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Randomization</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Allocation concealment</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Groups similar at baseline</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Participants blinded</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Staff delivering treatment blinded</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Groups treated the same except intervention</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Blinded outcomes assessors</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Standardized outcomes measurement</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Complete follow-up or differences described, analyzed</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Participants analyzed in randomization group</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Appropriate statistics</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Design appropriate and deviations from standard accounted for</bold>
</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_015" ref-type="bibr">Ahmed Ali 2022</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">Unclear</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Unclear</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_016" ref-type="bibr">Costa-Pinto 2022</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Unclear</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Unclear</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_019" ref-type="bibr">Davoudi-Monfared 2021</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Unclear</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Unclear</td><td align="left" valign="top" rowspan="1" colspan="1">Unclear</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Unclear</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_018" ref-type="bibr">Hussein El Adly 2022</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Unclear</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_021" ref-type="bibr">Lal 2021</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_023" ref-type="bibr">Santer 2020</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td></tr></tbody></table><table frame="hsides" rules="rows"><thead><tr><th colspan="12" align="left" valign="middle" rowspan="1">
<bold>Cohort Studies</bold>
</th></tr><tr><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Study</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Groups similar, from same population</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Exposures measured similarly</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Exposure measurement reliable, valid</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Confounders identified</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Strategies to address confounders described</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Groups free of outcome at start</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Outcomes measurement reliable, valid</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Follow-up time reported, sufficient for outcome to develop</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Follow-up complete or loss reasons described</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Strategies to address incomplete followup used</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Appropriate statistics</bold>
</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_020" ref-type="bibr">Kim 2021</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_026" ref-type="bibr">Levine 2013</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_022" ref-type="bibr">Macielak 2021</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_025" ref-type="bibr">Poveromo 2016</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_024" ref-type="bibr">Tremblay 2020</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_004" ref-type="bibr">Whitson 2016</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">Unclear</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">NA</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td></tr></tbody></table><table frame="hsides" rules="rows"><thead><tr><th colspan="11" align="left" valign="middle" rowspan="1">
<bold>Case Control Studies</bold>
</th></tr><tr><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Study</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Comparable groups</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Cases, controls appropriately matched</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Consistent criteria to ID cases, controls</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Exposure measurement standard, valid, reliable</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Exposure measurement standard for cases, controls</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Confounders identified</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Strategies to address confounders described</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Outcomes measurement standard, reliable, valid for cases, controls</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Exposure period long enough</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Appropriate statistics</bold>
</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Wood, 2022</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">Unclear</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td></tr></tbody></table><table frame="hsides" rules="rows"><thead><tr><th colspan="11" align="left" valign="middle" rowspan="1">
<bold>Case Series</bold>
</th></tr><tr><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Study</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Clear inclusion criteria</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Condition measurement reliable, valid</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Valid methods of case identification</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Consecutive case inclusion</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Complete inclusion of participants</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Clear demographic reporting</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Clear clinical info reporting</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Outcomes or follow-up results clearly reported</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Clear reporting of site demographics</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Appropriate statistics</bold>
</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_002" ref-type="bibr">Rizvi, 2018</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<xref rid="j_jccm-2025-0007_ref_003" ref-type="bibr">Rizvi, 2019</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Unclear</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td></tr></tbody></table><table-wrap-foot><fn id="j_jccm-2025-0007_tfn_009"><p>Abbreviation: NA, not applicable.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="j_jccm-2025-0007_s_004"><title>Discussion</title><p>This systematic review included 15 publications and 1,714 patients who received midodrine for shock and is the first to focus on the practical aspects of midodrine use. Important findings included the predominance of observational studies (60%) conducted at single centers (80%), reliance on a fixed dose of 10 mg three times daily or every 8 hours (47%), absence of a midodrine dosing protocol and wide variability in dose administered (5 to 120 mg total daily dose). Additionally, no study adjusted the dose for renal dysfunction, looked exclusively at patients not on IVPs, described IVP-related or central venous catheter-related complications, or included patients in an emergency department or rural setting. These findings suggest caution be used when interpreting or applying the existing data regarding midodrine use for shock.</p><p>Midodrine was used for a variety of shock types, including cardiogenic, spinal, septic, and post-operative shock, often combining all shock patients together. The most common indication for midodrine was to decrease the duration or intensity of IVPs. Avoiding IVPs entirely would obviate the need for a central line or ICU admission, which has only been commented on by Rivzi and colleagues [<xref rid="j_jccm-2025-0007_ref_002" ref-type="bibr">2</xref>,<xref rid="j_jccm-2025-0007_ref_003" ref-type="bibr">3</xref>]. Other potential benefits of midodrine use prior to or early with IVPs include decreasing fluid requirements or IVP requirements, possibly reducing risk for adverse events from IVPs. These endpoints have been understudied and only one publication reported time to first midodrine dose (13 hours) [<xref rid="j_jccm-2025-0007_ref_021" ref-type="bibr">21</xref>]. The majority focused on late use of midodrine when patients were weaning off low doses of IVPs.</p><p>Most publications reported midodrine dosing intervals of either every 8 hours or three times a day (possibly with a 12-hour gap without doses overnight) though a recent paper reported dosing every 6 hours [<xref rid="j_jccm-2025-0007_ref_022" ref-type="bibr">22</xref>]. When midodrine was FDA approved for symptomatic orthostatic hypotension, the prescribing information recommended dosing three times a day during daylight hours due to the risk of nocturnal supine hypertension. Dosing it every 8 hours has its drawbacks as the active metabolite of midodrine, desglymidodrine, has a duration of action of 2&#x02013;3 hours and a half-life of 3&#x02013;4 hours, which could lead to suboptimal dosing. Midodrine may be better suited for every 4- or 6-hour dosing to maintain adequate serum concentrations as suggested in studies of orthostatic hypotension [<xref rid="j_jccm-2025-0007_ref_005" ref-type="bibr">5</xref>] but this must be studied in patients with shock.</p><p>Most publications reported using midodrine in fixed doses. Intravenous vasopressors are titrated to an objective endpoint (e.g., mean arterial pressure); logically midodrine should be titrated to effect as well, supported by its FDA approved dosing. The studies that utilized dose titrations did not have protocols or guidance for how midodrine was titrated. Similarly, none of the randomized controlled trials allowed dose titrations, which raises the question of whether their overall negative findings would be different with titratable, optimized dosing protocols [<xref rid="j_jccm-2025-0007_ref_006" ref-type="bibr">6</xref>,<xref rid="j_jccm-2025-0007_ref_007" ref-type="bibr">7</xref>].</p><p>None of the included studies adjusted midodrine dosing for hepatic or renal dysfunction and those with end-organ injury were often excluded. The FDA label lists acute renal disease as a contraindication for use. Despite this, midodrine is commonly used to treat vasodilatory shock in patients with cirrhosis or during renal replacement therapy [<xref rid="j_jccm-2025-0007_ref_028" ref-type="bibr">28</xref>,<xref rid="j_jccm-2025-0007_ref_029" ref-type="bibr">29</xref>,<xref rid="j_jccm-2025-0007_ref_030" ref-type="bibr">30</xref>]. The lack of information related to the pharmacokinetics of midodrine absorption in shock or accumulation with repeated dosing in patients with renal or hepatic dysfunction should be addressed in future trials. The bioavailability of midodrine is 93% and not affected by food in healthy volunteers but no study has been conducted during critical illness or compared oral versus gastric tube administration.</p><p>Previously published meta-analyses reported findings focused on safety and effectiveness [<xref rid="j_jccm-2025-0007_ref_008" ref-type="bibr">8</xref>,<xref rid="j_jccm-2025-0007_ref_009" ref-type="bibr">9</xref>,<xref rid="j_jccm-2025-0007_ref_010" ref-type="bibr">10</xref>]. Our systematic review builds upon their findings by answering questions about the bedside approach to midodrine use and the clinical relevance of its adverse drug effects. We determined that starting doses of 10&#x02013;20 mg every 6 to 8 hours are most commonly prescribed. Although the studies included both fixed and titrated dosing, titration to an objective endpoint is prudent given the pharmacodynamic and pharmacokinetic properties of midodrine and the proven dose-response for blood pressure. Utilization of dosing protocols for IVPs and midodrine might improve the safety and effectiveness of both.</p><p>This systematic review has limitations, one of which is its semi-quantitative design. We chose not to pursue a full meta-analysis due to the heterogeneity and low quality of the data available. Though RCTs are generally considered the highest quality of evidence, many midodrine studies were unblinded, used fixed doses or dosing intervals twice as long as shown to be effective [<xref rid="j_jccm-2025-0007_ref_002" ref-type="bibr">2</xref>,<xref rid="j_jccm-2025-0007_ref_003" ref-type="bibr">3</xref>,<xref rid="j_jccm-2025-0007_ref_004" ref-type="bibr">4</xref>,<xref rid="j_jccm-2025-0007_ref_005" ref-type="bibr">5</xref>,<xref rid="j_jccm-2025-0007_ref_015" ref-type="bibr">15</xref>,<xref rid="j_jccm-2025-0007_ref_016" ref-type="bibr">16</xref>,<xref rid="j_jccm-2025-0007_ref_017" ref-type="bibr">17</xref>,<xref rid="j_jccm-2025-0007_ref_018" ref-type="bibr">18</xref>,<xref rid="j_jccm-2025-0007_ref_019" ref-type="bibr">19</xref>,<xref rid="j_jccm-2025-0007_ref_020" ref-type="bibr">20</xref>,<xref rid="j_jccm-2025-0007_ref_021" ref-type="bibr">21</xref>,<xref rid="j_jccm-2025-0007_ref_022" ref-type="bibr">22</xref>,<xref rid="j_jccm-2025-0007_ref_023" ref-type="bibr">23</xref>,<xref rid="j_jccm-2025-0007_ref_024" ref-type="bibr">24</xref>,<xref rid="j_jccm-2025-0007_ref_025" ref-type="bibr">25</xref>,<xref rid="j_jccm-2025-0007_ref_026" ref-type="bibr">26</xref>]. Accordingly, we felt that including a broader sample of published data may provide additional information despite potential decreases in quality. We acknowledge that norepinephrine equivalents may have variability based on differences in base formulation [<xref rid="j_jccm-2025-0007_ref_031" ref-type="bibr">31</xref>]. Our aggregation and interpretation of adverse drug effects was limited by the specificity with which they were reported; under reporting is likely with retrospective reviews. Additionally, definitions of how adverse effects were identified or defined varied and were sometimes absent altogether.</p><p>There are many possible directions for future investigators of midodrine's utility for shock including evaluating fixed versus titrated dosing, optimal dosing frequency (every 4, 6 or 8 hours), early initiation in the emergency department, use in rural hospital settings, pharmacokinetic studies of oral versus gastric tube administration, and endpoints related to avoiding IVPs, central venous catheters, and their related complications. In summation of the studies reviewed, we propose specific clinical scenarios and conditions where midodrine may either be considered for use or alternatively should be avoided (<xref rid="j_jccm-2025-0007_tab_007" ref-type="table">Table 7</xref>). However, overall, a better understanding of the optimal dosing strategy, pharmacokinetics, and clinical effectiveness of midodrine in the setting of shock is needed and should be a priority for investigators.</p><table-wrap position="float" id="j_jccm-2025-0007_tab_007"><label>Table 7.</label><caption><p>Where midodrine may be consider and avoided</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Some Experience &#x02013; Likely Safe</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Limited Experience &#x02013; Use Caution</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>No Experience &#x02013; Avoid Use</bold>
</th><th align="left" valign="middle" rowspan="1" colspan="1">
<bold>Contraindications for Use</bold>
</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Orthostatic hypotension</td><td align="left" valign="top" rowspan="1" colspan="1">Vasopressor sparing</td><td align="left" valign="top" rowspan="1" colspan="1">Cardiogenic shock</td><td align="left" valign="top" rowspan="1" colspan="1">Pheochromocytoma</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hemodialysis hypotension</td><td align="left" valign="top" rowspan="1" colspan="1">Mixed shock</td><td align="left" valign="top" rowspan="1" colspan="1">Cerebral vasospasm</td><td align="left" valign="top" rowspan="1" colspan="1">Thyrotoxicosis</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Septic Shock</td><td align="left" valign="top" rowspan="1" colspan="1">Renal failure</td><td align="left" valign="top" rowspan="1" colspan="1">Unknown enteral absorption</td><td align="left" valign="top" rowspan="1" colspan="1">Urinary retention</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Vasopressor weaning</td><td align="left" valign="top" rowspan="1" colspan="1">Lactate clearance</td><td align="left" valign="top" rowspan="1" colspan="1">Mechanical circulatory support</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hepatorenal syndrome</td><td align="left" valign="top" rowspan="1" colspan="1">Bradycardia</td><td align="left" valign="top" rowspan="1" colspan="1">Daily dose &#x0003e;120 mg</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Fixed dosing regimen</td><td align="left" valign="top" rowspan="1" colspan="1">Dosing every four hours</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Hepatic impairment</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Titrated dosing regimen</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr></tbody></table></table-wrap></sec><sec id="j_jccm-2025-0007_s_005"><title>Conclusion</title><p>The literature describing midodrine for blood pressure augmentation in shock is heterogeneous and comprised of mostly low-quality data, creating opportunities for future investigations. Controlled trials should carefully account for midodrine's initiation thresholds, dose titration strategies, and the clinical relevance of adverse drug effects to better describe its safety and effectiveness in shock.</p></sec></body><back><fn-group><fn fn-type="COI-statement"><p>
<bold>C<sc>onflict of interest</sc></bold>
</p><p>None to declare.</p></fn></fn-group><ref-list><title>References</title><ref id="j_jccm-2025-0007_ref_001"><label>1.</label><element-citation publication-type="book" publication-format="print"><source>ProAmatine&#x000ae; (midodrine hydrochloride) Tablets [package insert]</source><publisher-loc>Lexington, MA</publisher-loc><publisher-name>Shire US Inc</publisher-name><year>2017</year></element-citation></ref><ref id="j_jccm-2025-0007_ref_002"><label>2.</label><element-citation publication-type="journal" publication-format="print"><name><surname>Rizvi</surname><given-names>MS</given-names></name><name><surname>Trivedi</surname><given-names>V</given-names></name><name><surname>Nasim</surname><given-names>F</given-names></name><name><surname>Lin</surname><given-names>E</given-names></name><name><surname>Kashyap</surname><given-names>R</given-names></name><name><surname>Andrijasevic</surname><given-names>N</given-names></name><etal/><article-title>Trends in Use of Midodrine in the ICU: A Single-Center Retrospective Case Series</article-title><source>Crit Care Med</source><year>2018</year><volume>46</volume><issue>7</issue><fpage>e628</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">29613861</pub-id>
</element-citation></ref><ref id="j_jccm-2025-0007_ref_003"><label>3.</label><element-citation publication-type="journal" publication-format="print"><name><surname>Rizvi</surname><given-names>MS</given-names></name><name><surname>Nei</surname><given-names>AM</given-names></name><name><surname>Gajic</surname><given-names>O</given-names></name><name><surname>Mara</surname><given-names>KC</given-names></name><name><surname>Barreto</surname><given-names>EF</given-names></name><article-title>Continuation of Newly Initiated Midodrine Therapy After Intensive Care and Hospital Discharge: A Single-Center Retrospective Study</article-title><source>Crit Care Med</source><year>2019</year><volume>47</volume><issue>8</issue><fpage>e648</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">31107279</pub-id>
</element-citation></ref><ref id="j_jccm-2025-0007_ref_004"><label>4.</label><element-citation publication-type="journal" publication-format="print"><name><surname>Whitson</surname><given-names>MR</given-names></name><name><surname>Mo</surname><given-names>E</given-names></name><name><surname>Nabi</surname><given-names>T</given-names></name><name><surname>Healy</surname><given-names>L</given-names></name><name><surname>Koenig</surname><given-names>S</given-names></name><name><surname>Narasimhan</surname><given-names>M</given-names></name><etal/><article-title>Feasibility, Utility, and Safety of Midodrine During Recovery Phase From Septic Shock</article-title><source>Chest</source><year>2016</year><month>NaN</month><volume>149</volume><issue>6</issue><fpage>1380</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">26953217</pub-id>
</element-citation></ref><ref id="j_jccm-2025-0007_ref_005"><label>5.</label><element-citation publication-type="journal" publication-format="print"><name><surname>Wright</surname><given-names>RA</given-names></name><name><surname>Kaufmann</surname><given-names>HC</given-names></name><name><surname>Perera</surname><given-names>R</given-names></name><name><surname>Opfer-Gehrking</surname><given-names>TL</given-names></name><name><surname>McElligott</surname><given-names>MA</given-names></name><name><surname>Sheng</surname><given-names>KN</given-names></name><etal/><article-title>A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension</article-title><source>Neurology</source><year>1998</year><month>NaN</month><day>1</day><volume>51</volume><issue>1</issue><fpage>120</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">9674789</pub-id>
</element-citation></ref><ref id="j_jccm-2025-0007_ref_006"><label>6.</label><element-citation publication-type="journal" publication-format="print"><name><surname>Riker</surname><given-names>RR</given-names></name><name><surname>Gagnon</surname><given-names>DJ</given-names></name><article-title>Midodrine administration during critical illness: fixed-dose or titrate to response?</article-title><source>Intensive Care Med.</source><year>2021</year><month>NaN</month><day>25</day><volume>47</volume><issue>2</issue><fpage>249</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">33237345</pub-id>
</element-citation></ref><ref id="j_jccm-2025-0007_ref_007"><label>7.</label><element-citation publication-type="journal" publication-format="print"><name><surname>Riker</surname><given-names>RR</given-names></name><name><surname>Gagnon</surname><given-names>DJ</given-names></name><article-title>Letter to the Editor: &#x0201c;Midodrine to liberate ICU patients from intravenous vasopressors: Another negative fixed-dose trial&#x0201d;</article-title><source>J Crit Care</source><year>2022</year><month>NaN</month><volume>69</volume><fpage>153995</fpage><pub-id pub-id-type="pmid">35152142</pub-id>
</element-citation></ref><ref id="j_jccm-2025-0007_ref_008"><label>8.</label><element-citation publication-type="journal" publication-format="print"><name><surname>Al-Abdouh</surname><given-names>A</given-names></name><name><surname>Haddadin</surname><given-names>S</given-names></name><name><surname>Matta</surname><given-names>A</given-names></name><name><surname>Jabri</surname><given-names>A</given-names></name><name><surname>Barbarawi</surname><given-names>M</given-names></name><name><surname>Abusnina</surname><given-names>W</given-names></name><etal/><article-title>Impact of Adjuvant Use of Midodrine to Intravenous Vasopressors: A Systematic Review and Meta-Analysis</article-title><source>Crit Care Res Pract</source><year>2021</year><volume>2021</volume><fpage>5588483</fpage><pub-id pub-id-type="pmid">34055408</pub-id>
</element-citation></ref><ref id="j_jccm-2025-0007_ref_009"><label>9.</label><element-citation publication-type="journal" publication-format="print"><name><surname>Hamed</surname><given-names>M</given-names></name><name><surname>Elseidy</surname><given-names>SA</given-names></name><name><surname>Elkheshen</surname><given-names>A</given-names></name><name><surname>Maher</surname><given-names>J</given-names></name><name><surname>Elmoghrabi</surname><given-names>A</given-names></name><name><surname>Zaghloul</surname><given-names>A</given-names></name><etal/><article-title>The Use of Midodrine as an Adjunctive Therapy to Liberate Patients from Intravenous Vasopressors: A Systematic Review and Meta-analysis of Randomized Controlled Studies</article-title><source>Cardiol Ther</source><year>2023</year><month>NaN</month><volume>12</volume><issue>1</issue><fpage>185</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">36670331</pub-id>
</element-citation></ref><ref id="j_jccm-2025-0007_ref_010"><label>10.</label><element-citation publication-type="journal" publication-format="print"><name><surname>Hammond</surname><given-names>DA</given-names></name><name><surname>Smith</surname><given-names>MN</given-names></name><name><surname>Peksa</surname><given-names>GD</given-names></name><name><surname>Trivedi</surname><given-names>AP</given-names></name><name><surname>Balk</surname><given-names>RA</given-names></name><name><surname>Menich</surname><given-names>BE</given-names></name><article-title>Midodrine as an Adjuvant to Intravenous Vasopressor Agents in Adults With Resolving Shock: Systematic Review and Meta-Analysis</article-title><source>J Intensive Care Med</source><year>2020</year><month>NaN</month><volume>35</volume><issue>11</issue><fpage>1209</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">31030630</pub-id>
</element-citation></ref><ref id="j_jccm-2025-0007_ref_011"><label>11.</label><element-citation publication-type="journal" publication-format="print"><name><surname>Goradia</surname><given-names>S</given-names></name><name><surname>Sardaneh</surname><given-names>AA</given-names></name><name><surname>Narayan</surname><given-names>SW</given-names></name><name><surname>Penm</surname><given-names>J</given-names></name><name><surname>Patanwala</surname><given-names>AE</given-names></name><article-title>Vasopressor dose equivalence: A scoping review and suggested formula</article-title><source>J Crit Care</source><year>2021</year><month>NaN</month><volume>61</volume><fpage>233</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">33220576</pub-id>
</element-citation></ref><ref id="j_jccm-2025-0007_ref_012"><label>12.</label><element-citation publication-type="journal" publication-format="print"><name><surname>Barker</surname><given-names>TH</given-names></name><name><surname>Stone</surname><given-names>JC</given-names></name><name><surname>Sears</surname><given-names>K</given-names></name><name><surname>Klugar</surname><given-names>M</given-names></name><name><surname>Tufanaru</surname><given-names>C</given-names></name><name><surname>Leonardi-Bee</surname><given-names>J</given-names></name><etal/><article-title>The revised JBI critical appraisal tool for the assessment of risk of bias for randomized controlled trials</article-title><source>JBI Evid Synth</source><year>2023</year><month>NaN</month><day>1</day><volume>21</volume><issue>3</issue><fpage>494</fpage><lpage>506</lpage><pub-id pub-id-type="pmid">36727247</pub-id>
</element-citation></ref><ref id="j_jccm-2025-0007_ref_013"><label>13.</label><element-citation publication-type="journal" publication-format="print"><name><surname>Munn</surname><given-names>Z</given-names></name><name><surname>Barker</surname><given-names>TH</given-names></name><name><surname>Moola</surname><given-names>S</given-names></name><name><surname>Tufanaru</surname><given-names>C</given-names></name><name><surname>Stern</surname><given-names>C</given-names></name><name><surname>McArthur</surname><given-names>A</given-names></name><etal/><article-title>Methodological quality of case series studies: an introduction to the JBI critical appraisal tool</article-title><source>JBI Evid Synth</source><year>2020</year><month>NaN</month><volume>18</volume><issue>10</issue><fpage>2127</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">33038125</pub-id>
</element-citation></ref><ref id="j_jccm-2025-0007_ref_014"><label>14.</label><element-citation publication-type="book" publication-format="print"><article-title>Chapter 7: Systematic reviews of etiology and risk</article-title><source>JBI Manual for Evidence Synthesis</source><publisher-name>JBI</publisher-name><year>2020</year></element-citation></ref><ref id="j_jccm-2025-0007_ref_015"><label>15.</label><element-citation publication-type="journal" publication-format="print"><name><surname>Ahmed Ali</surname><given-names>AT</given-names></name><name><surname>Abd El-Aziz</surname><given-names>MA</given-names></name><name><surname>Mohamed Abdelhafez</surname><given-names>A</given-names></name><name><surname>Ahmed Thabet</surname><given-names>AM</given-names></name><article-title>Effect of Oral Vasopressors Used for Liberation from Intravenous Vasopressors in Intensive Care Unit Patients Recovering from Spinal Shock: A Randomized Controlled Trial</article-title><source>Crit Care Res Pract</source><year>2022</year><volume>2022</volume><fpage>6448504</fpage><pub-id pub-id-type="pmid">35087688</pub-id>
</element-citation></ref><ref id="j_jccm-2025-0007_ref_016"><label>16.</label><element-citation publication-type="journal" publication-format="print"><name><surname>Costa-Pinto</surname><given-names>R</given-names></name><name><surname>Yong</surname><given-names>ZT</given-names></name><name><surname>Yanase</surname><given-names>F</given-names></name><name><surname>Young</surname><given-names>C</given-names></name><name><surname>Brown</surname><given-names>A</given-names></name><name><surname>Udy</surname><given-names>A</given-names></name><etal/><article-title>A pilot, feasibility, randomised controlled trial of midodrine as adjunctive vasopressor for low-dose vasopressor-dependent hypotension in intensive care patients: The MAVERIC study</article-title><source>J Crit Care</source><year>2022</year><volume>67</volume><fpage>166</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">34801917</pub-id>
</element-citation></ref><ref id="j_jccm-2025-0007_ref_017"><label>17.</label><element-citation publication-type="journal" publication-format="print"><name><surname>Wood</surname><given-names>AJ</given-names></name><name><surname>Rauniyar</surname><given-names>R</given-names></name><name><surname>Jacques</surname><given-names>A</given-names></name><name><surname>Palmer</surname><given-names>RN</given-names></name><name><surname>Wibrow</surname><given-names>B</given-names></name><name><surname>Anstey</surname><given-names>MH</given-names></name><article-title>Oral midodrine does not expedite liberation from protracted vasopressor infusions: A case-control study</article-title><source>Anaesth Intensive Care</source><year>2023</year><month>NaN</month><volume>51</volume><issue>1</issue><fpage>20</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">36168754</pub-id>
</element-citation></ref><ref id="j_jccm-2025-0007_ref_018"><label>18.</label><element-citation publication-type="journal" publication-format="print"><name><surname>Adly</surname><given-names>DH El</given-names></name><name><surname>Bazan</surname><given-names>NS</given-names></name><name><surname>El Borolossy</surname><given-names>RM</given-names></name><name><surname>Anan</surname><given-names>IF</given-names></name><name><surname>Fakher</surname><given-names>MA</given-names></name><name><surname>El Wakeel</surname><given-names>LM</given-names></name><article-title>Midodrine improves clinical and economic outcomes in patients with septic shock: a randomized controlled clinical trial</article-title><source>Ir J Med Sci</source><year>2022</year><month>NaN</month><day>3</day></element-citation></ref><ref id="j_jccm-2025-0007_ref_019"><label>19.</label><element-citation publication-type="journal" publication-format="print"><name><surname>Davoudi-Monfared</surname><given-names>E</given-names></name><name><surname>Mohammadi</surname><given-names>M</given-names></name><name><surname>Khoshavi</surname><given-names>M</given-names></name><name><surname>Khalili</surname><given-names>H</given-names></name><article-title>The effect of midodrine on lactate clearance in patients with septic shock: a pilot study</article-title><source>J Comp Eff Res</source><year>2021</year><volume>10</volume><issue>8</issue><fpage>673</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">33860672</pub-id>
</element-citation></ref><ref id="j_jccm-2025-0007_ref_020"><label>20.</label><element-citation publication-type="journal" publication-format="print"><name><surname>Kim</surname><given-names>E</given-names></name><name><surname>Kast</surname><given-names>C</given-names></name><name><surname>Afroz-Hossain</surname><given-names>A</given-names></name><name><surname>Qiu</surname><given-names>M</given-names></name><name><surname>Pappas</surname><given-names>K</given-names></name><name><surname>Sinvani</surname><given-names>L</given-names></name><article-title>Bridging the Gap Between the Intensive Care Unit and the Acute Medical Care Unit</article-title><source>Am J Crit Care</source><year>2021</year><volume>30</volume><issue>3</issue><fpage>193</fpage><lpage>200</lpage><pub-id pub-id-type="pmid">34161979</pub-id>
</element-citation></ref><ref id="j_jccm-2025-0007_ref_021"><label>21.</label><element-citation publication-type="journal" publication-format="print"><name><surname>Lal</surname><given-names>A</given-names></name><name><surname>Trivedi</surname><given-names>V</given-names></name><name><surname>Rizvi</surname><given-names>MS</given-names></name><name><surname>Amsbaugh</surname><given-names>A</given-names></name><name><surname>Myers</surname><given-names>MK</given-names></name><name><surname>Saleh</surname><given-names>K</given-names></name><etal/><article-title>Oral Midodrine Administration During the First 24 Hours of Sepsis to Reduce the Need of Vasoactive Agents: Placebo-Controlled Feasibility Clinical Trial</article-title><source>Crit Care Explor</source><year>2021</year><month>NaN</month><day>6</day><volume>3</volume><issue>5</issue><fpage>e0382</fpage><pub-id pub-id-type="pmid">33977276</pub-id>
</element-citation></ref><ref id="j_jccm-2025-0007_ref_022"><label>22.</label><element-citation publication-type="journal" publication-format="print"><name><surname>Macielak</surname><given-names>SA</given-names></name><name><surname>Vollmer</surname><given-names>NJ</given-names></name><name><surname>Haddad</surname><given-names>NA</given-names></name><name><surname>Nabzdyk</surname><given-names>CGS</given-names></name><name><surname>Nei</surname><given-names>SD</given-names></name><article-title>Hemodynamic Effects of an Increased Midodrine Dosing Frequency</article-title><source>Crit Care Explor</source><year>2021</year><month>NaN</month><day>26</day><volume>3</volume><issue>4</issue><fpage>e0405</fpage><pub-id pub-id-type="pmid">33912835</pub-id>
</element-citation></ref><ref id="j_jccm-2025-0007_ref_023"><label>23.</label><element-citation publication-type="journal" publication-format="print"><name><surname>Santer</surname><given-names>P</given-names></name><name><surname>Anstey</surname><given-names>MH</given-names></name><name><surname>Patroc&#x000ed;nio</surname><given-names>MD</given-names></name><name><surname>Wibrow</surname><given-names>B</given-names></name><name><surname>Teja</surname><given-names>B</given-names></name><name><surname>Shay</surname><given-names>D</given-names></name><etal/><article-title>Effect of midodrine versus placebo on time to vasopressor discontinuation in patients with persistent hypotension in the intensive care unit (MIDAS): an international randomised clinical trial</article-title><source>Intensive Care Med</source><year>2020</year><volume>46</volume><issue>10</issue><fpage>1884</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">32885276</pub-id>
</element-citation></ref><ref id="j_jccm-2025-0007_ref_024"><label>24.</label><element-citation publication-type="journal" publication-format="print"><name><surname>Tremblay</surname><given-names>JA</given-names></name><name><surname>Laram&#x000e9;e</surname><given-names>P</given-names></name><name><surname>Lamarche</surname><given-names>Y</given-names></name><name><surname>Denault</surname><given-names>A</given-names></name><name><surname>Beaubien-Souligny</surname><given-names>W</given-names></name><name><surname>Frenette</surname><given-names>AJ</given-names></name><etal/><article-title>Potential risks in using midodrine for persistent hypotension after cardiac surgery: a comparative cohort study</article-title><source>Ann Intensive Care</source><year>2020</year><month>NaN</month><day>14</day><volume>10</volume><issue>1</issue><fpage>121</fpage><pub-id pub-id-type="pmid">32926256</pub-id>
</element-citation></ref><ref id="j_jccm-2025-0007_ref_025"><label>25.</label><element-citation publication-type="journal" publication-format="print"><name><surname>Poveromo</surname><given-names>LB</given-names></name><name><surname>Michalets</surname><given-names>EL</given-names></name><name><surname>Sutherland</surname><given-names>SE</given-names></name><article-title>Midodrine for the weaning of vasopressor infusions</article-title><source>J Clin Pharm Ther</source><year>2016</year><month>NaN</month><volume>41</volume><issue>3</issue><fpage>260</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">26945564</pub-id>
</element-citation></ref><ref id="j_jccm-2025-0007_ref_026"><label>26.</label><element-citation publication-type="journal" publication-format="print"><name><surname>Levine</surname><given-names>AR</given-names></name><name><surname>Meyer</surname><given-names>MJ</given-names></name><name><surname>Bittner</surname><given-names>EA</given-names></name><name><surname>Berg</surname><given-names>S</given-names></name><name><surname>Kalman</surname><given-names>R</given-names></name><name><surname>Stanislaus</surname><given-names>AB</given-names></name><etal/><article-title>Oral midodrine treatment accelerates the liberation of intensive care unit patients from intravenous vasopressor infusions</article-title><source>J Crit Care</source><year>2013</year><month>NaN</month><volume>28</volume><issue>5</issue><fpage>756</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">23845791</pub-id>
</element-citation></ref><ref id="j_jccm-2025-0007_ref_027"><label>27.</label><element-citation publication-type="journal" publication-format="print"><name><surname>Whitson</surname><given-names>MR</given-names></name><name><surname>Mo</surname><given-names>E</given-names></name><name><surname>Nabi</surname><given-names>T</given-names></name><name><surname>Healy</surname><given-names>L</given-names></name><name><surname>Koenig</surname><given-names>S</given-names></name><name><surname>Narasimhan</surname><given-names>M</given-names></name><etal/><article-title>Feasibility, Utility, and Safety of Midodrine During Recovery Phase From Septic Shock</article-title><source>Chest</source><year>2016</year><month>NaN</month><volume>149</volume><issue>6</issue><fpage>1380</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">26953217</pub-id>
</element-citation></ref><ref id="j_jccm-2025-0007_ref_028"><label>28.</label><element-citation publication-type="journal" publication-format="print"><name><surname>Sujith Reddy</surname><given-names>JSN</given-names></name><name><surname>Jagtap</surname><given-names>N</given-names></name><name><surname>Kalpala</surname><given-names>R</given-names></name><name><surname>Kulkarni</surname><given-names>A</given-names></name><name><surname>Gupta</surname><given-names>R</given-names></name><name><surname>Nagaraja Rao</surname><given-names>P</given-names></name><etal/><article-title>Midodrine versus Albumin to Prevent Paracentesis Induced Circulatory Dysfunction in Acute on Chronic Liver Failure Patients in the Outpatient Clinic-a Randomized Controlled Trial</article-title><source>J Clin Exp Hepatol</source><year>2023</year><volume>13</volume><issue>4</issue><fpage>576</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">37440947</pub-id>
</element-citation></ref><ref id="j_jccm-2025-0007_ref_029"><label>29.</label><element-citation publication-type="journal" publication-format="print"><name><surname>Shrestha</surname><given-names>DB</given-names></name><name><surname>Budhathoki</surname><given-names>P</given-names></name><name><surname>Sedhai</surname><given-names>YR</given-names></name><name><surname>Baniya</surname><given-names>RK</given-names></name><name><surname>Karki</surname><given-names>P</given-names></name><name><surname>Jha</surname><given-names>P</given-names></name><etal/><article-title>Midodrine in Liver Cirrhosis With Ascites: A Systematic Review and Meta-Analysis</article-title><source>Cureus</source><year>2022</year><month>NaN</month><volume>14</volume><issue>7</issue><fpage>e27483</fpage><pub-id pub-id-type="pmid">36060403</pub-id>
</element-citation></ref><ref id="j_jccm-2025-0007_ref_030"><label>30.</label><element-citation publication-type="journal" publication-format="print"><name><surname>Brunelli</surname><given-names>SM</given-names></name><name><surname>Cohen</surname><given-names>DE</given-names></name><name><surname>Marlowe</surname><given-names>G</given-names></name><name><surname>Van Wyck</surname><given-names>D</given-names></name><article-title>The Impact of Midodrine on Outcomes in Patients with Intradialytic Hypotension</article-title><source>Am J Nephrol</source><year>2018</year><volume>48</volume><issue>5</issue><fpage>381</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">30423552</pub-id>
</element-citation></ref><ref id="j_jccm-2025-0007_ref_031"><label>31.</label><element-citation publication-type="journal" publication-format="print"><name><surname>Mongardon</surname><given-names>N</given-names></name><name><surname>de Roux</surname><given-names>Q</given-names></name><name><surname>Leone</surname><given-names>M</given-names></name><name><surname>Guerci</surname><given-names>P</given-names></name><article-title>Norepinephrine formulation for equivalent vasopressive score</article-title><source>Crit Care</source><year>2023</year><month>NaN</month><day>16</day><volume>27</volume><issue>1</issue><fpage>62</fpage><pub-id pub-id-type="pmid">36797766</pub-id>
</element-citation></ref></ref-list></back></article>